<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Stories by Zoey Li on Medium]]></title>
        <description><![CDATA[Stories by Zoey Li on Medium]]></description>
        <link>https://medium.com/@zoeylwm?source=rss-8a3f268f949e------2</link>
        <image>
            <url>https://cdn-images-1.medium.com/fit/c/150/150/1*AU5eIWvPZ6Aetf8D1d2EHA.png</url>
            <title>Stories by Zoey Li on Medium</title>
            <link>https://medium.com/@zoeylwm?source=rss-8a3f268f949e------2</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Sun, 22 Nov 2026 22:12:40 GMT</lastBuildDate>
        <atom:link href="https://medium.com/@zoeylwm/feed" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[The Care Economy Is Bigger Than You Think. And It’s Being Disrupted in Three Different Ways]]></title>
            <link>https://medium.com/@zoeylwm/the-care-economy-is-bigger-than-you-think-and-its-being-disrupted-in-three-different-ways-e23dc72d758e?source=rss-8a3f268f949e------2</link>
            <guid isPermaLink="false">https://medium.com/p/e23dc72d758e</guid>
            <category><![CDATA[caregivers]]></category>
            <category><![CDATA[healthcare-technology]]></category>
            <category><![CDATA[healthcare]]></category>
            <category><![CDATA[venture-capital]]></category>
            <category><![CDATA[investing]]></category>
            <dc:creator><![CDATA[Zoey Li]]></dc:creator>
            <pubDate>Sat, 25 Apr 2026 20:33:06 GMT</pubDate>
            <atom:updated>2026-04-25T20:33:06.112Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/841/1*KC0kUgIXChnGEqn84fZF9g.jpeg" /></figure><p>There’s a version of the care economy story that gets told a lot. The workforce is aging out. Family caregivers are burning out unpaid. The labor shortage is structural. Medicaid is underfunded. Home-based care is the future but nobody has figured out how to make it work at scale.</p><p>All of that is true. What doesn’t get told as often is what’s happening on the other side of that problem: the founders and operators who are actually building into the dysfunction and, in some cases, quietly building very good businesses.</p><p>Over the past several months, I’ve spent time deep in three companies operating across different corners of the care economy: Abby Care (pediatric IDD), Hera (senior care navigation), and Scriptify (pharmacy-embedded chronic care). They don’t look the same on the surface. But they’re each attacking the same underlying truth: care delivery in the United States is expensive, fragmented, and labor-constrained. And the incumbents have no real incentive to fix it.</p><p>What follows is my attempt to map the different flavors of disruption happening right now, and what I think each one actually gets right.</p><p>But before getting to the companies, there’s a framing point worth making, because it shapes how I think about all three of them.</p><p>Tech-enabled services has a complicated history. A lot of those companies struggled in the 2022 cycle, and the core reason was structural: the margin profile was still too close to the underlying services business. You were adding a technology layer on top of human labor-intensive delivery, but you weren’t fundamentally changing the economics. The result was companies that looked like software but had the unit economics of staffing firms.</p><p>I think AI changes that calculus. The shift happening now is from tech-enabled services / SaaS to what some are calling “services as software”: instead of buying a tool, you’re buying the outcome. AI agents become the labor, and the software becomes the service delivery mechanism. The operational efficiency gains, automation of clinical documentation, eligibility identification, care coordination workflows, start to look genuinely transformative for margin. Businesses that previously required a lot of human touches per unit of output suddenly don’t.</p><p>But here’s the thing: if operational automation becomes commoditized, then the question stops being who has the best AI and starts being who owns distribution. Whoever controls the patient relationship and the workflow integration has the durable advantage. If you only have the automation layer, you still need to acquire customers, run a sales motion, and integrate into existing systems. That’s hard, expensive, and doesn’t compound the way distribution does. So the real question in evaluating any of these businesses isn’t just how good the technology is. It’s whether they own distribution or just the automation, and whether the two can be separated.</p><p>All three of the companies I’ll talk about are doing something interesting on both dimensions. Each has a structural claim on distribution that isn’t easy to replicate, and each is using technology to compress the human labor intensity that historically made services businesses hard to scale. That combination is what makes them worth paying attention to.</p><h3>The Structure of the Problem</h3><p>Before getting to the companies, it’s worth being precise about the problem, because “the care economy is broken” is too vague to be useful.</p><p>There are actually at least three distinct failure modes, and they compound each other.</p><p>The first is <strong>supply-side failure</strong>. Home-based care is structurally undersupplied. Traditional home care agencies face chronic labor shortages: the work is physically demanding, wages are low relative to other options, and<a href="https://homehealthcarenews.com/2024/07/home-cares-industry-wide-turnover-rate-reaches-nearly-80/"> turnover runs north of 50% annually in many segments</a>. States want more care delivered in the home because<a href="https://www.ahcancal.org/Assisted-Living/Facts-and-Figures/Pages/default.aspx"> it’s dramatically cheaper than institutional settings</a> (think $20–50K per year for home care versus $90–120K+ for nursing facility care), but there’s no workforce to do it.</p><p>The second is <strong>navigation failure</strong>. The system is too complex for the people who most need to use it. Families managing aging parents, kids with disabilities, or medically complex relatives are left to figure out Medicaid waiver structures, prior auth processes, care coordination between providers, and discharge planning essentially on their own. There’s no dedicated professional whose job is to guide you through it, not in the way a lawyer guides you through legal complexity or an accountant guides you through a tax situation.</p><p>The third is <strong>reimbursement access failure</strong>. Some of the most trusted and high-frequency care touchpoints in the country (community pharmacies) have been structurally locked out of the reimbursement system for the clinical work they already do informally. Every time a Medicare patient asks a pharmacist whether it’s safe to take two medications together, or gets a reminder about a missed glucose reading, that is a billable clinical interaction worth $50 under <a href="https://www.humhealth.com/blog/chronic-care-management-cpt-codes-and-billing-guide-2025/">Medicare’s CPT codes</a>. But pharmacies have lacked the clinical staffing, compliance infrastructure, and billing capability to capture it. The revenue already exists; the infrastructure to claim it doesn’t.</p><p>Each of the companies I’ll talk about is taking a different one of these failure modes as its primary wedge.</p><h3>Flavor One: Creating Supply from Scratch (<a href="https://www.abbycare.org/">Abby Care</a>)</h3><p>The most interesting thing about Abby Care isn’t the technology. It’s the labor economics insight underneath it.</p><p>Traditional home care agencies face a structural supply problem: there aren’t enough people willing to do the work at the wages Medicaid reimbursement supports. Abby Care sidesteps this entirely. Rather than recruiting strangers into caregiving jobs, their model converts family members who are <em>already</em> providing care, unpaid, into formally trained, W-2 employees reimbursed through Medicaid.</p><p>The before-and-after is stark. Before Abby Care: a parent caring for a child with IDD, receiving zero compensation, no training, no formal support. After: that same parent earns a wage through Medicaid, has been trained by Abby Care, and is backed by compliance, clinical oversight, and administrative infrastructure. The state gets what it wanted: more care delivered in the home at a fraction of institutional cost. The family gets what it needed: economic recognition for care it was already giving.</p><p>This is what Abby Care means when they talk about being a consumer-directed platform. They’re not managing a caregiver workforce so much as formalizing one that already exists. And because the “workforce” is already living with the patient, the recruiting cost, the commute problem, and the turnover problem mostly disappear.</p><p>The model plugs into state Medicaid programs, primarily operating outside traditional waiver structures in many states, though the <a href="https://www.medicaidplanningassistance.org/home-community-based-services/">waiver ecosystem</a> is the relevant market context. The state sets a reimbursement rate, Abby Care pays the caregiver a wage, and the spread between reimbursement and fully-loaded caregiver cost (i.e., minus compliance, technology, and administrative overhead) is the margin pool the business operates on.</p><p>The reason Abby Care wins against traditional providers in their segment isn’t price or even technology. It’s that their cost structure is fundamentally different. A traditional agency carries high fixed costs, heavy staff turnover, and recruiting overhead. Abby Care’s “staff” is already in the client’s home. That structural gap is the whole thesis.</p><p>The expansion question is where things become more nuanced. The pediatric model works cleanly in part because there is typically a highly engaged parent already providing care in the home: a natural, present actor who both wants to do the work and is structurally positioned to deliver consistent support. That makes it easier to formalize and compensate care that is already happening.</p><p>As the model expands into other populations, that dynamic can become less consistent. Caregiving arrangements may involve aging parents, siblings across households, or fragmented support systems, and in some cases there may be no clear primary caregiver at all. The core insight, converting existing informal care into paid and structured care, relies on that underlying care infrastructure already being present. Understanding where this dynamic holds as reliably as it does in pediatrics is one of the key questions in evaluating how broadly the model can scale.</p><p>But the broader point stands: Abby Care isn’t just building another home care company. They’re solving the supply problem by looking for supply where traditional agencies never thought to look.</p><h3>Flavor Two: Building a New Profession (<a href="https://hellohera.com/">Hera</a>)</h3><p>Hera is trying to do something harder, and in some ways more interesting: create a new professional category from scratch.</p><p>The insight is that families navigating complex healthcare situations such as aging parents, post-discharge care coordination, insurance navigation are systematically underserved because there is no dedicated professional whose job is to guide them through it. Hera calls this role a “Hero.” Think of it as a geriatric care manager crossed with a case manager crossed with a healthcare system translator: someone who can coordinate follow-up care, navigate prior auths, make sure the discharge plan actually works at home, and help families figure out the next step.</p><p>Demand isn’t the problem. Hera already has seven-figure GMV and gets most customers through referrals from geriatricians, hospital social workers, and health systems. The feedback is strong. The constraint is supply: finding, hiring, and scaling the people who can do this job.</p><p>The challenge is that the role requires three very different skill sets simultaneously: building family trust in high-stress situations, navigating healthcare system complexity, and doing a large amount of operational coordination. Historically, geriatric care managers are the closest profession, but it’s a tiny talent pool and not a scalable hiring base.</p><p>Hera’s solution is to unbundle the role by standardizing workflows and making complex system knowledge more accessible. The idea is that someone earlier in their career, a new social work grad, a junior nurse looking for an alternative to hospital life, can take on the Hero role and lean on the platform for the system knowledge they don’t yet have. Early cohorts apparently validate this approach.</p><p>The bigger question is where the economics land. If the role market-clears around nurse-level compensation (<a href="https://drive.google.com/file/d/1PBXI9q_G-BmrzTywX_ZdRtfL3D1CbLHo/view?usp=sharing">$60+/hr fully loaded in NY once you factor in healthcare and employer taxes</a>), and it’s currently out-of-pocket for families, the addressable market skews toward the affluent. That’s not a small market, and it may be the right starting point, but the long-term scale story depends on whether this can get covered. Medicare’s chronic care management infrastructure, and the broader momentum toward reimbursed care navigation, is the policy tailwind. Companies like <a href="https://www.solace.health/">Solace</a> are navigating similar questions.</p><p>The workforce question is where it gets interesting. There’s a sweet spot between credential level, regulatory exposure, and labor cost. If the platform is genuinely handling the knowledge and coordination layer, the role might work with a lower-credential candidate profile than a traditional care manager, which dramatically expands the labor pool while keeping unit economics intact. One cohort that may be hiding in plain sight: <a href="https://www.kff.org/racial-equity-and-health-policy/what-role-do-immigrants-play-in-the-hospital-workforce/">immigrant populations who trained as nurses abroad but don’t yet have U.S. licensure</a>. Many end up in adjacent healthcare roles despite strong clinical backgrounds. Given Hera’s model of unbundling and upskilling, that’s a pool worth exploring; the clinical instincts are already there, and what’s missing is system knowledge, which is exactly what the platform provides.</p><p>But there’s a real tension in how far down the credential ladder you can go. Clinical moments are unpredictable. What starts as a logistics call can surface something serious: a medication change, a safety concern, a moment that requires clinical judgment and a direct line to a provider. A coordinator-tier Hero handling that in real time, without the standing or training to respond, doesn’t just create a gap; it can break the trust that made the relationship valuable in the first place. The answer isn’t necessarily to credential up at every touchpoint. It’s to build the care model so that clinical backup is ambient: fast, invisible to the family, and already looped in before the handoff shows. Get that right and the credential question opens up considerably.</p><p>The question for Hera is whether the virtual delivery model and the platform layer they’re building can get the workforce economics to a place where the service is scalable and the margin is sustainable, without sacrificing the quality of relationship that makes the category work in the first place.</p><p>I think the category is real and underbuilt. The execution question is live.</p><h3>Flavor Three: Unlocking a Hidden Revenue Layer (<a href="https://www.scriptifyrx.com/">Scriptify</a>)</h3><p>There’s a quiet crisis unfolding at the corner of almost every underserved neighborhood in America.<a href="https://www.pharmacytimes.com/view/ncpa-2024-in-spite-of-challenges-independent-pharmacies-are-continuing-to-serve-patients"> More than 20,000 independent pharmacies</a> collectively serve upwards of 50 million elderly patients managing multiple conditions and medications.<a href="https://publichealth.berkeley.edu/articles/spotlight/research/nearly-1-in-3-retail-pharmacies-have-closed-since-2010"> More than a third of those pharmacies have closed since 2010, at a pace of more than one per day.</a> The cause of death is usually the same:<a href="https://www.ftc.gov/system/files/ftc_gov/pdf/pharmacy-benefit-managers-staff-report.pdf"> dispensing margins have been squeezed to nothing by PBM reimbursement cuts</a>, and there’s no other meaningful revenue stream to replace them. But the deeper problem is structural. The independent pharmacy has never been recognized for what it actually is: one of the most consistent, trusted, and clinically active touchpoints in the American healthcare system.</p><p>The cost runs beyond the pharmacies themselves. The patients who depend on them, often older, managing multiple conditions and without easy access to primary care, don’t get that access point back when it closes. And the clinical work that happens at the counter every day, the drug interaction questions, the adherence check-ins, the early flags on worsening conditions, none of it gets captured. It happens, it helps, and then it disappears. No record, no continuity, no reimbursement. The healthcare system is quietly hemorrhaging clinical value it doesn’t even know it’s generating.</p><p>Scriptify’s core bet is that this is worth fixing, and that fixing it requires building infrastructure that didn’t previously exist. The company operates as a telemedicine clinic, embedding alongside independent pharmacies to extend the clinical relationship that begins at the point of dispensing. Licensed clinicians conduct regular telehealth touchpoints with enrolled patients, creating a continuity of care layer that the pharmacy relationship makes possible but has never been able to sustain on its own.</p><p>What’s notable about the model is what it doesn’t require. It doesn’t ask pharmacies to become something they’re not. It doesn’t disrupt dispensing workflows or add operational burden to already stretched pharmacy teams. And it doesn’t ask patients to seek out a new provider; it meets them where the relationship already exists. The pharmacy remains the trusted face; Scriptify provides the clinical and administrative infrastructure operating quietly behind it.</p><p>The strategic logic is sound. Scriptify integrates on top of existing pharmacy management systems without requiring workflow changes, new hires, or retraining. Eligibility identification, patient enrollment, clinical staffing, documentation, and billing are all absorbed into the clinic infrastructure, leaving the pharmacy to do what it already does. The result is an adoption curve that looks less like a technology implementation and more like flipping a switch. That frictionlessness shows up in the traction: pharmacies are signing up ahead of the first pilot going live, which suggests the problem is felt urgently enough that operators aren’t waiting for proof before signing on.</p><p>The open questions are the ones any infrastructure play in healthcare has to answer. Reimbursement policy is a real dependency; the programs that make this model viable have been tightened before and could be again. Patient engagement rates for telephonic outreach need to hold at scale, across geographies and demographics that vary considerably. And the long-term competitive question, whether a well-capitalized EHR vendor or national pharmacy chain eventually decides to replicate this, is real. The moat today is relational and operational: pharmacy owner trust, workflow integration, and the compounding value of having gotten there first.</p><p>What’s easy to miss in the near-term framing is the structural asset being built underneath it. Every clinical interaction Scriptify conducts generates something the healthcare system is genuinely short of: structured, longitudinal evidence about how patients with complex medication regimens are actually doing between physician visits. That gap matters for how care gets coordinated, for how drug efficacy gets understood in real-world populations, for how health systems think about intervention timing. Scriptify isn’t primarily positioning itself as a data company, but it is becoming one, methodically and perhaps inevitably. The pharmacy is the access point. The telemedicine clinic is the mechanism. What accumulates over time is something the market hasn’t fully priced yet.</p><h3>What Connects Them</h3><p>These three companies look different: different populations, different business models, different economic structures. But they’re all responding to the same underlying architecture problem in American care delivery.</p><p>The system was built around acute, institutional, episodic care. What people actually need, especially disabled populations, seniors, and anyone with chronic or complex conditions is continuous, home-based, relationship-centered care. The infrastructure for that didn’t really get built. The workforce wasn’t trained or paid for it. The accountability mechanisms weren’t designed for it. The administrative tools weren’t designed for it.</p><p>What’s happening now, across these companies and others, is a slow reconstruction of that infrastructure. Abby Care is building supply-side architecture. Hera is building navigation architecture. Scriptify is building reimbursement access architecture.</p><p>None of them are going to fix the system alone. But each is building something that the system structurally needs and didn’t previously have.</p><p>The macro tailwind is real and durable: Medicaid programs are under fiscal pressure and strongly prefer home-based care over institutional care. The population of people who need ongoing, complex support is growing. The workforce shortage is structural and not going away. Medicare is actively expanding reimbursement pathways for community-based chronic care, with programs like <a href="https://pubmed.ncbi.nlm.nih.gov/41004609/">Advanced Primary Care Management (APCM) launched last year</a>. And the policy direction at both federal and state levels is toward more care at home, more accountability for outcomes, and more clinical responsibility for the settings where patients actually show up.</p><p>The companies that will win in this space are the ones who understand that care economy disruption isn’t one thesis: it’s three different ones, attacking different failure modes in the same broken system. And what ties them together isn’t just the problem they’re solving. It’s that each of them owns distribution in a way that’s hard to replicate, and each is using technology to compress the human labor intensity that historically made services businesses hard to scale. That combination, distribution plus automation, is what the next generation of durable care economy companies looks like.</p><p>That convergence is further out. But I think we’re watching the foundation get laid.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=e23dc72d758e" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[The Forgotten Children]]></title>
            <link>https://medium.com/@zoeylwm/the-forgotten-children-d54f4b9a8147?source=rss-8a3f268f949e------2</link>
            <guid isPermaLink="false">https://medium.com/p/d54f4b9a8147</guid>
            <category><![CDATA[healthcare-technology]]></category>
            <category><![CDATA[surgery]]></category>
            <category><![CDATA[venture-capital]]></category>
            <category><![CDATA[healthcare]]></category>
            <category><![CDATA[technology]]></category>
            <dc:creator><![CDATA[Zoey Li]]></dc:creator>
            <pubDate>Sat, 18 Apr 2026 21:28:12 GMT</pubDate>
            <atom:updated>2026-04-18T21:28:12.187Z</atom:updated>
            <content:encoded><![CDATA[<p><strong>Why outpatient surgery is about to get a software company, a payer story, and a new class of operator all at the same time</strong></p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*aWolqeAQx-Nun_lPJdYUQA.jpeg" /></figure><p>Here is a story a healthcare corp dev executive told me earlier this month.</p><p>His health system runs a bunch of hospitals. Each hospital runs an orthopedic service line. Each orthopedic service line does a lot of knee replacements. A knee replacement in a hospital outpatient department carries a facility fee of roughly $15,000 to $20,000. The same procedure, done the same day, in an ambulatory surgery center (ASC) a mile down the road carries a facility fee of roughly $6,000 to $9,000.</p><p>His system’s payers have been asking for years why they are paying the higher number when the clinical outcomes are the same. Meanwhile, his system’s own ACO, the value-based care arm that gets paid when total cost of care goes down, has been asking the same question, internally, for the same reason.</p><p>Nothing moves.</p><p>“The hospital wants more procedures in hospital outpatient because it’s more lucrative,” a population health specialist at Epic who works with these systems told me. “But the pop health arm wants more in ASCs because it’s more opportunity for savings.”</p><p>Two arms of the same building, pointed in opposite directions, neither with authority over the other. Multiply this by every health system in America and you have a pretty good explanation for why a procedure shift that should have taken five years has been taking twenty.</p><p>The shift is happening anyway. It just isn’t happening through hospitals.</p><h3>The thesis in one paragraph</h3><p>The ASC market is a $73B-and-growing category that sits inside a $5T system, running on software built in the early 2000s, with no operational intelligence layer, no AI layer, no clean data infrastructure, and no one in charge of any of that. Procedures are migrating out of hospitals anyway because CMS keeps adding more of them to the outpatient-allowed list, because hospital reimbursement for surgeons is compressing, and because payers are explicitly steering volume to lower-cost sites. The incumbent operators, large private equity-backed rollups and hospital-ASC joint ventures, are competing on contracted payer rates and capital. None of them are building the data infrastructure that value-based care will eventually require. A new class of operator that owns the physical center, owns the software layer, and brings surgeons in as co-owners can build a data moat the incumbents cannot replicate on their existing cost bases. The window to do this before the big guys figure out they need to is open now.</p><p>That’s the argument. Let’s get into it.</p><h3>Section 1: Everything happening in the space</h3><h3>The migration is real, large, and structurally one-way</h3><p>Outpatient surgery has been growing for decades, but the last few years are different in character. The CMS inpatient-only list, the list of procedures Medicare requires be done on an admitted basis, has been shrinking. Total knee replacement came off the list. Total hip, some spine fusions, and a growing list of cardiovascular procedures have followed. When a procedure leaves that list, two things happen: the procedure becomes eligible for outpatient reimbursement, and commercial payers update their coverage policies in the same direction.</p><p>A Harvard-trained neurosurgeon I spoke with put the mechanism plainly: “A few years ago, total joint replacement came off of the inpatient-only list. The physicians realized that if they keep patients out of the hospital and do them at the surgery center, they can benefit. Also, they’re decreasing reimbursement for surgery, so we’re doing the same work for less. Owning a surgery center is one way to counteract that.”</p><p>Two pressures stacked on top of each other: policy opens the door, and reimbursement compression pushes surgeons through it. That’s why the migration isn’t going to stop. It doesn’t depend on one regulation or one payer. It depends on physicians protecting their income in a world where clinic reimbursement sits around $200 per hour, barely enough to cover overhead.</p><h3>The economics flow somewhere, and it isn’t to patients</h3><p>The 40–60% cost savings between a hospital outpatient department and an ASC are real. They just don’t flow evenly.</p><ul><li><strong>Payers win.</strong> Almost all of the savings land with the insurer. A knee replacement that cost the payer $30,000 in a hospital lands at $15,000 in an ASC. The payer keeps that delta.</li><li><strong>Physician-owners win.</strong> They capture the facility fee on top of the professional fee. A surgeon earning $1,500–$3,000 in professional fee per case can earn a share of a $15,000–$25,000 facility fee if they own the center.</li><li><strong>Patients mostly don’t feel it.</strong> Flat copays mean a $250 out-of-pocket on a $30,000 hospital procedure is the same as a $250 out-of-pocket on a $15,000 ASC procedure. The exception is high-deductible plans paying coinsurance, where the patient feels the full savings differential. Most people don’t.</li><li><strong>Hospitals lose.</strong> If a hospital system loses 500 knee replacements a year to ASCs, it loses $5–7M in facility fee revenue. At scale, across orthopedics, spine, cardiology, GI, ENT, this is existential for hospital systems that depend on high-margin elective surgery to cross-subsidize emergency care and indigent care.</li></ul><p>The result is a structurally misaligned system in which the entity that controls scheduling (hospitals, via employed surgeons) has every reason to keep volume in hospital outpatient, while everyone else in the system, payers, physician-owners, their own ACOs, has every reason to move it out. The migration happens primarily through independent physicians, because hospital-employed physicians can’t or won’t break their block time to operate at an ASC they don’t own.</p><h3>The technology underneath is 20 years old</h3><p>If you asked a software engineer to design an EHR for ASCs today, they would not design SIS Complete or HST Pathways. Both are early-2000s systems built for a world where the back-office job was data entry and compliance, not optimization. Neither has operational intelligence. Neither has an AI layer. Neither integrates well with the other components of the stack: billing, scheduling, prior auth, supply, pre-op clearance, anesthesia billing.</p><p>Most ASCs run a patchwork: SIS Complete or HST Pathways for the EHR, separate billing software, manual scheduling, a spreadsheet somewhere tracking OR utilization. The operator I spoke with, who runs multiple centers and just sold one, was direct: “Pretty much all healthcare workers from doctors to nurses are incredibly technology-averse. It’s like a full-time person pretty much doing just data entry. Nobody really takes care of this.”</p><p>There is typically no internal software champion. No CTO. No IT lead. Technology decisions are delegated to an external consultant who treats software as background infrastructure. When it breaks, someone gets on the phone. When it works, no one pays attention to it.</p><p>The metrics that matter to operators, OR utilization, contribution margin by surgeon, are tracked manually or not at all. Contribution margin by surgeon is the metric every operator I heard from said they most wanted and could least reliably get. Legacy surgeons are carried at or below break-even because nobody has the visibility to cut them. That is a software failure that costs real money, every month, in every center that exists.</p><h3>Utilization is the single biggest number nobody is solving</h3><p>The average ASC runs at 60–65% OR utilization. The well-run ones push 80–85%. The gap is 20+ points of throughput on the same fixed cost base.</p><p>A center with six OR hours a day running at 65% is running 3.9 hours of cases and sitting idle for 2.1 hours while paying rent, staff, anesthesia, and equipment costs in full. Pushing that to 80% means nearly one additional case per day. At $15,000–$25,000 in facility fees per case, that’s $15,000–$25,000 in incremental daily revenue before any cost change.</p><p>Annualize it and you have $4M–$6M of revenue per center per year sitting on the floor. Nobody is systematically picking it up because nobody has the data to see it.</p><h3>Consolidation is accelerating, and nobody is building tech</h3><p>The competitive landscape, roughly:</p><ul><li><strong>The three largest ASC management platforms </strong>(USPI, Amsurg, SCA Health) are acquiring centers aggressively, and all three are now owned by strategic acquirers rather than financial sponsors. USPI sits inside Tenet (the hospital system). SCA Health sits inside Optum (the UnitedHealth subsidiary). Amsurg was acquired by Ascension in June 2025 for $3.9 billion, another health system buying its way into ambulatory surgery at scale. The playbook inside these platforms is still PE style (buy EBITDA, apply multiple arbitrage, consolidate for payer leverage), but the long-term incentives of the parents are strategic, not financial.</li><li><strong>Health systems</strong> are entering through 51/49 JVs with the management platforms. AdventHealth’s model is representative: AdventHealth brings capital and its contracted payer rates; SCA Health runs the center day-to-day. The strategy is explicitly defensive. “Private equity comes into the market and is buying surgery centers in our market,” the AdventHealth corp dev team told me. “Whether we are on the train or not, more and more surgeries are moving into that setting. We can either be a part of it or not be a part of it.”</li><li><strong>Physician-owned centers</strong> are still the majority of the market, but are under pressure from both directions. The physicians can get more per case by joining a hospital JV (because health systems have bigger contracted rates). They can get liquidity by selling to PE. Mid-to-late-career surgeons are taking those deals.</li><li><strong>Medtech vendors</strong>: Intuitive Surgical, Stryker, Medtronic and Boston Scientific are increasingly embedded in ASCs on the clinical side and are starting to look at how to extend their product footprint into adjacent workflow software. None of them own centers, so none of them have the longitudinal patient outcomes data to make those models work.</li></ul><p>And the technology layer sits empty. Nobody in the incumbent stack is building an AI native operating system for ASCs. The management platforms don’t because their operating playbook is financial even when the parent isn’t, and product investment isn’t on the plan. The hospital JVs don’t because they delegate technology decisions to those management partners. None of the management partners are software companies. Optum is the interesting exception: UnitedHealth has real technology DNA elsewhere in the org, but those assets aren’t ASC focused and the integration cost to repurpose them is non trivial, so SCA keeps running on existing infrastructure. SIS Complete and HST Pathways are 20 year old products and act like it.</p><p>This is what I mean by “forgotten children.” It is a real market, with real money, and no one is building the software layer for it.</p><h3>Section 2: What will matter</h3><p>If that’s what’s happening, here is what will actually determine who wins the next decade.</p><h3>1. Whoever aligns the physician controls the volume</h3><p>The single most important fact about ASCs is that they do not exist without physicians. You cannot conjure cases into a building; the surgeons bring them. Which means surgeon recruitment and surgeon retention are the only real growth channels.</p><p>A healthcare BD veteran I spoke with, who’s recruited surgeons into new centers for decades, was emphatic that the pitch that actually moves surgeons is not the investment return. It’s lifestyle. “You can go home to your family at nighttime. If you have block time at the surgery center, it’s not like the hospital where it stays open all the time. There’s an end to look forward to.” The economics close the deal. Time and autonomy open it.</p><p>This has two implications. First, any operator model that treats surgeons as customers rather than owners is going to lose surgeons as soon as someone offers them ownership. Second, any operator that can credibly promise less administrative friction, absorbing the data entry, the credentialing, the prior auth, the billing, has a recruiting advantage independent of economics.</p><h3>2. The rate gap is a near-term problem that becomes a long-term advantage</h3><p>Today, a hospital-ASC JV wins on rates. AdventHealth doing tens of thousands of cases a year negotiates commercial rates per CPT code that are meaningfully higher than what a standalone ASC doing 3,000 cases can get. When they take controlling interest and apply those rates, revenue per procedure goes up immediately without anything changing clinically. For a surgeon doing 200 cases a year at $1,000–$2,000 more per procedure under health system rates, that’s $200K–$400K in incremental annual revenue. That’s the financial case for the JV.</p><p>That math holds under fee-for-service. It does not hold under value-based care. Under VBC, payment is based on outcomes and efficiency, not negotiated rate schedules. The thing that determines your revenue is the quality of your longitudinal outcomes data. A health system-affiliated ASC managed by SCA Health has no longitudinal outcomes data infrastructure. An AI-native operator that owns the data layer does.</p><p>The question is not whether VBC becomes the dominant contracting structure in surgery. It will, the same way it did in primary care, just slower. The question is timeline. If you believe VBC surgery contracting is five years out, the rate gap is the binding constraint today and the operator model has to recruit surgeons who value the long-term trade-off. If you believe it’s ten years out, the rate gap is a bigger moat for the JV model.</p><p>Either way, whoever is building the data infrastructure now has the option on the VBC world. Whoever isn’t, doesn’t.</p><h3>3. Technology is not being priced into ASC valuations yet</h3><p>Every source I spoke with independently confirmed this. When health systems and PE firms evaluate an ASC acquisition, they look at case volume trajectory, financial performance, physician flight risk, and specialty mix. Technology infrastructure is not on the list. It is not priced into valuations.</p><p>This is good news and bad news. The good news: it means a tech-forward operator can acquire high-performing centers at current market rates and create technology-driven value the seller couldn’t monetize. The bad news: it means technology is not yet a competitive differentiator at the point of acquisition. The differentiation has to come from post-close value creation: better utilization, better contribution margin visibility, automated referral generation through surgeon spotlights, eventual VBC contracting premiums.</p><p>The bet is that as the market matures, technology infrastructure will command a valuation premium that buyers are not yet paying for. An AI-native operator acquiring at today’s prices is buying that premium at a discount.</p><h3>4. The operational data layer is defensible. The clinical data layer isn’t.</h3><p>Intuitive Surgical has been training models on surgical video for over 20 years across thousands of procedures globally. Stryker and Medtronic have similar datasets. A new ASC operator is not going to out-train them on intraoperative clinical AI. Anyone who tries is going to burn money building the wrong thing.</p><p>What those companies don’t have, and can’t easily get, is operational data: case duration by surgeon, prior auth denial risk, OR turnover patterns, patient dropout risk between diagnosis and procedure, scheduling adherence, contribution margin by specialist. That data flows around the surgery, not inside it. You can only capture it if you own the center.</p><p>This is the split that matters: partner on clinical, own operational. Medtech companies are natural clinical AI partners and natural operational AI competitors if you give them the data to become one. A well-structured partnership looks like de-identified longitudinal patient outcomes in exchange for embedded intraoperative AI. A badly structured partnership lets the medtech firm use your operational data to build their own platform and sell it to every other ASC.</p><h3>5. The end-to-end chain is the moat; point tools are not</h3><p>The ASC workflow is: patient intake → scheduling and prior auth → staffing and supply prep → OR and case capture → room turnover → documentation and billing. Point tools can improve individual links. The defensible moat comes from closing the entire chain and owning the data flow across it.</p><p>Nobody is doing this today. Incumbents built each piece separately, on different technology generations, with different data models. A full-stack operator that owns the center can close the loops a third-party SaaS vendor never can, because the SaaS vendor is always integrating into somebody else’s legacy stack. That integration problem is exactly why SIS Complete and HST Pathways have been unchallenged for 20 years because displacing them piece by piece is hopeless, and nobody has tried to own the whole thing at once.</p><h3>Section 3: Where value accrues</h3><p>Given the above, here is where I think the dollars actually land in the next decade.</p><h3>Facility fees will flow to whoever captures physician loyalty</h3><p>The total facility fee pool migrating from hospitals to ASCs is in the tens of billions over the next decade. How it splits is a function of who owns the centers those physicians work at. The split looks roughly like this:</p><ul><li><strong>Health system JVs</strong> will capture a material share, call it 30–40% of new case migration, because they’re moving first, have capital, and bring rate advantages. But they have a ceiling imposed by physician autonomy concerns. Surgeons who don’t want to give up board control won’t take those deals regardless of the rate uplift.</li><li><strong>The big consolidated platforms (USPI, SCA, Amsurg, and smaller PE-backed rollups below them) </strong>will capture another large chunk, probably 20–30%, purely on financial execution. Their long-term defensibility is weak because they’re not building product moats. At exit, they will be valued on multiples of EBITDA, not on data assets.</li><li><strong>Independent physician-owned centers</strong> will remain a large installed base but will shrink as a share of new build-out because capital availability is on the side of the rollups.</li><li><strong>AI-native full-stack operators</strong>, a category that barely exists yet, have the opportunity to capture the surgeons who want co-ownership equity and technology leverage without giving up governance to a hospital system. If they execute, the upside is a disproportionate share of the most growth-oriented, quality-focused surgeons.</li></ul><h3>Contribution margin by surgeon is an unmet need that converts</h3><p>Any platform that automatically surfaces contribution margin by specialist becomes indispensable to operators. It’s the single most requested metric in the category. It’s what lets operators cut loss-making surgeon relationships, prioritize high-margin specialties for recruiting, and make intelligent capital allocation decisions about which specialty lines to expand.</p><p>No incumbent system provides it. It is a real white space, not a “wouldn’t it be nice” feature.</p><h3>The surgeon scorecard is an automated referral engine</h3><p>Primary care physicians refer to surgeons they trust. Surgeons build that trust manually over years through relationships, networking, and word of mouth. A platform that automatically generates tiered performance scorecards, volume by procedure type, same-day discharge rates, patient-reported outcomes (the safe-to-share metrics; complication rates stay internal because of risk adjustment problems), and distributes them to PCP referral networks is, in effect, automated business development for every surgeon in the network simultaneously.</p><p>The value compounds with network size. More centers means more surgeons, more spotlights, more PCPs in the distribution, stronger referral patterns. That’s a network effect that doesn’t exist in traditional ASCs because the surgeon has no incentive to share their data and the operator has no incentive to surface it.</p><h3>Longitudinal outcomes data is VBC currency</h3><p>The path to risk contracts with Medicare Advantage plans, commercial payers, and self-insured employers runs through longitudinal outcomes data. A payer signing a bundled payment contract for orthopedic surgery wants to see that your network runs complication rates below the national benchmark, discharge times faster than the hospital standard, and readmission rates inside a specific envelope. That data needs to be structured, queryable, and credible, meaning systematically captured rather than self-reported.</p><p>Most ASC operators don’t have this data because their infrastructure doesn’t capture it. Most surgeons track their own outcomes in personal Excel spreadsheets. Epic, at the hospital level, has no complication query function. The data exists nowhere in structured, queryable form. An operator that systematically captures it has an option on VBC contracting that everyone else in the category can’t exercise.</p><p>One caveat: payer contracting is a relationship business. Data gets you to the table. People you know get you in the room. The operators that do this well will pair the data infrastructure with M&amp;A of smaller national VBC players that bring the relationships, because buying existing relationships is faster than building new ones.</p><h3>Agentic interop replaces the integration tax</h3><p>Traditional EHR integration, building API pipelines between system A and system B, costs tens to hundreds of thousands of dollars per integration, takes months to implement, and breaks when either side updates. This is why most ASCs just don’t integrate. They hire data entry staff and move on.</p><p>Agentic AI potentially collapses that cost toward zero. An AI agent logs into the legacy system as a user, reads the data it needs, and inputs it into the target system the way a human would, but automated. If it works reliably, the integration cost per acquired center drops dramatically, which makes M&amp;A rollup strategies meaningfully more scalable.</p><p>The reliability and compliance questions are real. Patient safety means audit trails and human-in-the-loop are non-negotiable. But the direction of travel is clear, and it heavily favors operators who are already thinking in terms of agentic workflows rather than hand-coded integrations.</p><h3>Device company partnerships unlock the clinical AI layer</h3><p>Clinical AI, the intraoperative decision support, the surgical field analysis, is where the medtech incumbents will win. Trying to compete with Intuitive on robotic surgery models is a losing bet. Partnering with them is a winning one, as long as you’re the one who controls the operational data moat.</p><p>The structure that works is: medtech gets de-identified clinical outcomes data for clinical model improvement only. The operator keeps operational data, scheduling, case economics, surgeon utilization, explicitly out of scope. The medtech gets a better surgical AI. The operator gets intraoperative clinical AI embedded without building it. Both sides compound.</p><p>The structure that doesn’t work is any agreement where the medtech gets operational data. That data is the moat. Giving it away dissolves the reason the operator exists.</p><h3>Section 4: Business models that will outperform</h3><h3>The AI-native, full-stack, surgeon co-owned operator</h3><p>This is the model that wins if it executes. The features:</p><ul><li><strong>Owns the physical center.</strong> This is what lets you capture the facility fee, control the environment, and own the data flow. SaaS overlays don’t work because there’s no software champion to buy them in most ASCs, and because SaaS can only improve the links they integrate with, not close the full chain.</li><li><strong>Owns the software layer.</strong> This is what creates the data moat. Built inside the operator’s own centers, co-developed with the surgeons and staff who use it, trained on every case that runs through the network. No external vendor has this adjacency.</li><li><strong>Brings surgeons in as co-owners.</strong> This is what turns performance data from surveillance into alignment. A surgeon who has equity in the center has a direct economic stake in utilization, turnover, and quality. Performance dashboards become tools they want, not threats they resist.</li><li><strong>Pursues de novo and M&amp;A in parallel.</strong> De novo centers generate clean, standardized data from day one but are slow and capital-intensive. M&amp;A is capital-efficient, buy existing volume, layer on the software, normalize the data over 12 months, but creates integration work. Running both gives you speed plus data purity.</li><li><strong>Positions for VBC explicitly.</strong> Every product decision is made with the question of “does this make our outcomes data more credible to a payer?” The value creation path runs through eventual risk contracts, not just fee-for-service arbitrage on facility fees.</li></ul><p><a href="https://oathsurgical.com/">Oath Surgical</a> is the clearest public example of an operator trying to build exactly this model. Four centers as of early 2026, all centers profitable at the unit level, and an <a href="https://www.fiercebiotech.com/medtech/ai-native-outpatient-surgery-startup-oath-surgical-inks-nvidia-partnership">NVIDIA partnership on the real-time AI infrastructure</a>. That’s not the only company that could pursue this shape, but it is the cleanest illustration of what the model looks like.</p><h3>The consolidation play without tech</h3><p>Still works financially. Buy EBITDA at 6–8x, apply multiple arbitrage at exit, consolidate for payer leverage. The outcomes are decent but capped. For the PE-owned versions, exit valuations are multiples of EBITDA, not strategic premiums for data assets. For the strategically-owned versions (USPI/Tenet, SCA/Optum, Amsurg/Ascension), the returns are captured through payer contracting synergies and volume retention, which is meaningful but also capped. And as the rate gap compresses, which it will as VBC contracting becomes more common in surgery, the multiple arbitrage thesis weakens.</p><p>This model will continue to generate returns in the near term. It won’t generate the kind of outsized outcome that a category defining tech enabled operator would, because there is no structural moat, just balance sheet and sourcing discipline.</p><h3>The hospital-ASC JV</h3><p>Works in the near term on rate arbitrage. Struggles in the long term on three axes. First, physician autonomy: surgeons who resist giving up majority control won’t accept the JV structure regardless of the rate case. Second, operational competency: hospitals aren’t good at running ASCs, which is why they outsource to SCA. Third, technology: hospital systems are not going to build the software layer themselves, and their management partners (SCA, USPI) aren’t software companies. They will continue to look like capital plus brand plus contracted rates, which is a model that works when fee-for-service is the dominant contracting structure and starts to look thin when VBC takes hold.</p><h3>The pure software overlay (SaaS into third-party ASCs)</h3><p>This is the tempting model that I think is mostly a trap at this stage. The distribution challenge is real: no internal software champion means you have to create the buyer, not find them. The sales cycle is long and expensive. The integration cost into legacy systems eats into margin. You also can’t close the full chain, because the center’s existing workflows are running on incumbent systems you don’t control.</p><p>The model likely works eventually, once a full-stack operator has reference customers, outcome data, and a proven product, and then opens the platform to third-party licensing from a position of strength. Leading with pure SaaS licensing before owning centers is the inverse of the right sequence.</p><h3>The single-specialty ASC</h3><p>Underappreciated business model. A center focused entirely on, say, orthopedic spine or outpatient joint replacement or GI, with staff who do the same handful of procedures every day, runs dramatically better than a multi-specialty center. Staff build deep familiarity. Surgeon preferences stabilize. Supply chain is simpler. Utilization benchmarks are higher. One surgeon I spoke with who ran a single-specialty spine ASC said staff quality was meaningfully better than the hospital, purely because the procedures were consistent enough for pattern recognition to develop.</p><p>The ceiling is addressable market: a single-specialty center can’t flex into other specialties if volume softens. But for operators targeting specific high-growth procedure categories, outpatient joint replacement, spine, cardiovascular, single-specialty is probably the right shape, and probably a better model than the multi-specialty rollup from a unit economics perspective.</p><h3>Section 5: What competitors will do</h3><p>Forecasting what the other players do over the next five years:</p><h3>Large health systems</h3><p>Will continue to acquire ASCs defensively through JV structures with SCA, USPI, and similar management partners. Will continue to delegate technology decisions to those management partners. Will not build in-house software capability because it is not their core competency and the ROI case isn’t there versus the capital they’re deploying on center acquisitions.</p><p>Their window to counter an AI-native model is open now and will close if they don’t move in the next three to five years. They won’t. The internal dynamics (hospital P&amp;L vs. ACO P&amp;L misalignment, tech delegated to JV partners, corp dev teams valuing technology at zero) don’t support the investment decisions that would be required.</p><p>They are a competitive threat on surgeon recruitment through rate arbitrage today. They are not a competitive threat on technology moat, now or soon.</p><h3>Large ASC platforms inside strategic parents (USPI/Tenet, SCA/Optum, Amsurg/Ascension)</h3><p>Will continue rolling up at aggressive pace. Will continue not building product. Will have meaningful payer side leverage at scale that a smaller operator can’t match. Will face margin compression as rate arbitrage works less well in a VBC world.</p><p>The strategic parents all have the capital and the strategic rationale to invest in technology inside their ASC platforms. None has shown signs of doing it at the depth required to build an AI native operating system. Optum is the most interesting case because UnitedHealth has real technology DNA elsewhere in the org, but those assets aren’t ASC focused and the integration cost to repurpose them is high, so SCA keeps running on legacy infrastructure. Ascension just completed its Amsurg integration and is focused on payer contracting synergies, not software. Tenet has owned USPI for years and has never invested meaningfully in the technology layer.</p><p>The most likely competitive move from this camp is a late, defensive acquisition of an AI native operator once the category becomes visible enough that capital markets price it. That acquisition window is the exit opportunity for the early movers.</p><h3>Incumbent ASC EHR vendors (SIS Complete, HST Pathways)</h3><p>Will bolt AI features onto 20-year-old codebases. Will market heavily on being “AI-enabled.” Will not credibly deliver end-to-end optimization because their architectures were never designed for it. A 20-year-old EHR with an AI scribe module bolted on is not the same thing as an AI-native operating system, and operators will figure this out once they see the difference.</p><p>The likely move is acquisition by a larger platform: either a PE rollup that wants to bring EHR capability in-house, or a medtech vendor building a broader workflow platform. That acquisition doesn’t solve the architecture problem.</p><h3>Medtech vendors (Intuitive, Stryker, Medtronic, Boston Scientific)</h3><p>Will continue to dominate clinical AI. Will push harder into adjacent operational workflow software, with mixed results because they lack operational data. Will be excellent partners for operators that know how to structure the data exchange correctly and protect the operational moat. Will be dangerous partners for operators that don’t.</p><p>The strategic question for a medtech firm is whether to build their own ASC workflow platform (hard, because they don’t own centers) or to partner with operators who do (easier, but creates dependency). Most of them will try a bit of both. The ones that partner well will see their clinical AI get better faster because they’ll have access to longitudinal outcomes data they’ve never had before.</p><h3>Payers</h3><p>Will push VBC contracting in surgery, slowly but persistently. Will run small pilots with operators that have credible outcomes data. Will steer Medicare Advantage volume toward lower-cost sites through network design and member incentives. Will not build their own provider networks at scale, despite Optum’s vertical integration model, because the capital requirements and execution risk are high.</p><p>The window for an early-moving operator to sign bundled payment and shared savings contracts at favorable terms, because the payer is buying learning is roughly the next 24–36 months. After that, payers will have standardized their ASC-specific VBC structures and the contracts will look more like commoditized fee schedules.</p><h3>Hospitals (as operators, not JV partners)</h3><p>Will lose high-margin elective surgical volume. Will respond with some combination of: tighter non-compete and exclusivity terms for employed physicians (slows migration but doesn’t stop it), their own internal ambulatory surgery buildouts (works in markets where the hospital has the scale and isn’t already partnered with SCA), and political pressure on CMS to slow the inpatient-only list changes (low probability of success; the cost savings math is too clean).</p><p>The honest assessment is that hospitals are losing a financial battle they are structurally mispositioned to win. Their revenue model depends on cross-subsidizing unprofitable care with profitable surgical volume, and that cross-subsidy is evaporating one CPT code at a time.</p><h3>Physicians (as a class)</h3><p>Will continue to accept co-ownership deals. Will choose between hospital JVs (more rate, less control) and physician-aligned operators (less rate today, more control plus equity upside and tech leverage). The split will correlate with career stage: mid-to-late career surgeons seeking liquidity take the JV; younger, growth-oriented, quality-focused surgeons take the co-ownership equity play. Both models will coexist for the next decade. Neither makes the other obsolete.</p><h3>What could go wrong</h3><p>A few honest risks to the thesis.</p><p><strong>VBC takes longer than expected.</strong> Surgery VBC has been “coming” for a decade. It’s earlier-stage than primary care VBC because episodic care is harder to contract for than longitudinal care. If it takes ten years instead of five, the rate gap is a bigger problem for tech-native operators and the payoff timeline extends.</p><p><strong>Physician flight risk on M&amp;A.</strong> If you buy a center and the physicians leave, you’ve bought an empty building. Every acquisition has to underwrite physician retention explicitly. This is more of an execution risk than a market risk, but it’s the execution risk that kills the most deals.</p><p><strong>Integration complexity on M&amp;A.</strong> Different acquired centers running different legacy systems means different normalization projects. Data quality across the network is heterogeneous until at least 12 months after integration. The AI flywheel depends on clean data; acquisition pace has to match the team’s ability to standardize.</p><p><strong>Ambient capture is harder than it looks.</strong> Surgeons operate in near-silence after 20 years of habit. AI scribes that assume narration don’t work. Useful ambient capture in the OR is probably camera-based timing data for OR flow (when the patient came in, when anesthesia started, when the incision happened, when turnover began) not clinical documentation. The product wedge is narrower than the marketing usually suggests.</p><p><strong>Medtech misplays the partnership.</strong> If a medtech firm gets access to operational data through a poorly-structured partnership and uses it to build a competing workflow platform, the data moat dissolves. Contracting discipline matters here more than almost any other single decision.</p><p>None of these are fatal. All of them are manageable with the right team and the right pace. They are the reason the thesis is a thesis and not a certainty.</p><h3>The shape of the winner</h3><p>If I had to sketch what the winning operator of the ASC category looks like in five years, it would look like this.</p><p>Thirty to fifty centers, concentrated in handful of specialties where ASC economics are strongest: orthopedics, spine, GI, ENT, outpatient cardiology, women’s health. All running on a single AI-native platform that captures every case. Surgeons across the network hold meaningful equity stakes; the network has recruited against hospital JVs by leading with lifestyle and autonomy, with equity upside as the closer.</p><p>The platform has automated the pain points no one else was solving: contribution margin by surgeon is surfaced in real time. Turnover timing is measured and continuously optimized. Prior auth denial risk is flagged before claims are submitted. Patient engagement between diagnosis and procedure has reduced dropout materially. Surgeon spotlights run on a cadence without anyone touching them, driving referral volume into every surgeon in the network simultaneously.</p><p>The data layer has matured enough to support bundled payment contracts with three to five regional payers: Medicare Advantage plans and self-insured employers to start. Outcomes data from tens of thousands of procedures is credibly better than the hospital benchmarks on complication rates, readmission rates, and cost per episode. Shared savings contracts are a meaningful revenue line, not just a slide in the deck.</p><p>The operator has partnership agreements with two or three medtech vendors on clinical AI, structured so operational data stays inside. The clinical AI embedded in the platform is better than what a non-partnered operator could build. The operational data moat is intact.</p><p>The big consolidated platforms are still bigger by center count. Health system JVs still win on rate in specific markets. The AI native operator is the one everyone in the category has started benchmarking against, and acquisition offers from the strategic parents and the large health systems are starting to come in.</p><p>That’s the shape. The thesis is that the window to build it is open now. Capital, regulation, and physician economics are all pointing in the same direction for maybe the first time in this market’s history. The technology layer is empty. The incumbents are incentivized not to build it.</p><p>Someone will. The question is who moves fast enough to matter.</p><p><em>Field research underlying this thesis: nine interviews across operators, surgeons, health systems, medtech, payers, and value-based care.</em></p><p><em>Operators and commercial: a multi-center ASC operator with U.S. and German exposure who recently sold a center, and a healthcare sales and BD veteran with over two decades covering USPI, SCA, and Amsurg accounts.</em></p><p><em>Surgeons: a board-certified neurosurgeon (Harvard trained) who also serves as a medical director at a national commercial health insurer, a neurosurgery and endovascular fellow, a colorectal surgeon and robotic MIS fellow, and an adult reconstruction surgeon specializing in robotic joint replacement.</em></p><p><em>Health systems: corporate development leaders at a large health system actively expanding its ASC portfolio.</em></p><p><em>Medtech: a senior AI/ML and market research lead at the interventional spine division of a major medical device manufacturer.</em></p><p><em>Population health and VBC: a long-tenured implementation consultant at Epic focused on VBC technology and the hospital-to-ASC volume migration.</em></p><p><em>All quotes anonymized or paraphrased to source category.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=d54f4b9a8147" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Exploring Consumer Through a Healthcare Lens]]></title>
            <link>https://medium.com/@zoeylwm/exploring-consumer-through-a-healthcare-lens-1b07b6ed5649?source=rss-8a3f268f949e------2</link>
            <guid isPermaLink="false">https://medium.com/p/1b07b6ed5649</guid>
            <category><![CDATA[venture-capital]]></category>
            <category><![CDATA[investing]]></category>
            <category><![CDATA[digital-health]]></category>
            <category><![CDATA[consumer-behavior]]></category>
            <category><![CDATA[healthcare]]></category>
            <dc:creator><![CDATA[Zoey Li]]></dc:creator>
            <pubDate>Sun, 15 Feb 2026 22:47:46 GMT</pubDate>
            <atom:updated>2026-02-15T22:47:46.857Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*Saqf8DXTXShSsk5RuyY-qw.png" /></figure><p>Recently, a VC asked me to put together some thoughts on the consumer space.</p><p>I took it on partly as an intellectual exercise, a way to better understand business models outside my core focus, and partly because consumer sits in an interesting adjacency to healthcare. Different dynamics, different pace, but surprising overlap in behavior, trust, and habit formation.</p><p>While I’ve spent most of my time in healthcare, it was genuinely refreshing to zoom out and study consumer more directly. And since this thinking may be useful to others navigating similar intersections, I’m sharing a snapshot here.</p><p>Over the past 2+ years, I’ve been fortunate to build deep relationships with founders across early-stage startups. Below are ten that I find particularly interesting, spanning consumer, healthcare, and the increasingly blurred line between the two.</p><h3><a href="https://www.neurovitalsai.com/">NeuroVitals</a> (Pre-Seed)</h3><p><strong>What they’re building:<br></strong>A metabolic-science-driven approach to mental health using lab data, AI-guided interventions, and habit-forming micro-actions.</p><p><strong>Why it’s compelling:<br></strong>Instead of competing with therapy, NeuroVitals reframes psychiatric care through a biologically grounded, outcomes-first lens in the ~$280B U.S. mental health market.</p><p><strong>Founder:<br></strong><a href="https://www.linkedin.com/in/william-furness-64864930/">William Furness</a>: repeat healthcare founder and former unicorn mental-health CEO (Thriveworks).</p><h3><a href="https://www.dognosis.tech/">Dognosis</a> (Pre-Seed)</h3><p><strong>What they’re building:<br></strong>A multi-cancer early detection platform powered by AI and canine olfactory signals via a low-cost breath test.</p><p><strong>Why it’s compelling:<br></strong>Early cancer detection is expensive, invasive, or inaccessible. Dognosis dramatically lowers both friction and price, shifting screening upstream into a consumer-friendly experience.</p><p><strong>Founder:<br></strong><a href="https://www.linkedin.com/in/akashkulgod/">Akash Kulgod</a>: UC Berkeley–trained cognitive scientist and canine neuroscience researcher.</p><h3><a href="https://www.galenai.com/">Galen</a> (Pre-Seed)</h3><p><strong>What they’re building:<br></strong>A personal healthcare companion that unifies medical records and wearable data into a persistent health memory.</p><p><strong>Why it’s compelling:<br></strong>Generic AI chat lacks continuity and trust. Galen focuses on durable context — turning fragmented, reactive care into an ongoing consumer experience.</p><p><strong>Founder:<br></strong><a href="https://www.linkedin.com/in/virajmehta28/">Viraj Mehta</a>: Stanford-trained computer scientist and YC founder.</p><h3><a href="https://www.matchwithmashi.com/">Mashi</a> (Pre-Seed)</h3><p><strong>What they’re building:<br></strong>The “Common App for pet adoption,” centralizing matching and coordination across shelters.</p><p><strong>Why it’s compelling:<br></strong>Pet adoption remains fragmented and high-friction within the ~$150B U.S. pet industry. Mashi wedges itself into the highest-trust moment in the pet lifecycle: adoption, which creates a natural path toward becoming a long-term operating system for next-gen pet owners.</p><p><strong>Founder:<br></strong><a href="https://www.linkedin.com/in/petrajanney/">Petra Janney</a>: longtime animal welfare operator and co-founder of Amelia Air, a nonprofit that has flown thousands of shelter pets to safety since 2019.</p><h3><a href="https://soundhealth.life/">SoundHealth</a> (Seed)</h3><p><strong>What they’re building:<br></strong>FDA-cleared, AI-personalized acoustic therapy for respiratory and sleep care.</p><p><strong>Why it’s compelling:<br></strong>Clinically backed relief delivered through a frictionless, at-home daily habit across a ~$40B+ market.</p><p><strong>Founder:<br></strong><a href="https://www.linkedin.com/in/paramesh-gopi-10b1b9114/">Paramesh Gopi</a>: serial entrepreneur and former public-company CEO.</p><h3><a href="https://www.abbycare.org/">Abby Care</a> (Seed)</h3><p><strong>What they’re building:<br></strong>A platform that turns family caregivers into paid, licensed CNAs.</p><p><strong>Why it’s compelling:<br></strong>Addresses a core supply bottleneck in the ~$100B+ home care market by unlocking an existing, trusted workforce.</p><p><strong>Founder:<br></strong><a href="https://www.google.com/search?q=Havi+Nguyen&amp;oq=abby+care+founder+&amp;gs_lcrp=EgZjaHJvbWUqBwgAEAAYgAQyBwgAEAAYgAQyBggBEEUYQDIICAIQABgWGB4yCAgDEAAYFhgeMg0IBBAAGIYDGIAEGIoFMg0IBRAAGIYDGIAEGIoFMgoIBhAAGIAEGKIEMgoIBxAAGIAEGKIE0gEIMTg3OWowajeoAgCwAgA&amp;sourceid=chrome&amp;ie=UTF-8&amp;ved=2ahUKEwiPr-f3m7mSAxWpEVkFHdJBG90QgK4QegYIAQgAEAQ">Havi Nguyen</a>: product operator shaped by firsthand caregiving experience.</p><h3><a href="https://www.generationlab.com/">Generation Lab</a> (Seed)</h3><p><strong>What they’re building:<br></strong>Organ-specific biological aging diagnostics using epigenetics.</p><p><strong>Why it’s compelling:<br></strong>Transforms aging from a vague wellness concept into a measurable, actionable signal in longevity and preventive health.</p><p><strong>Founder:<br></strong><a href="https://www.linkedin.com/in/alinasu/">Alina Rui Su</a>: bioengineer and aging researcher.</p><h3><a href="https://eggplan.co/">eggPlan</a> (Pre-Seed)</h3><p><strong>What they’re building:<br></strong>AI-driven fertility predictions with refund-backed guarantees.</p><p><strong>Why it’s compelling:<br></strong>Replaces uncertainty with measurable certainty and aligned incentives in the fertility services market.</p><p><strong>Founder:<br></strong><a href="https://www.linkedin.com/in/abhiwaud/">Abhi Waud</a>: repeat founder and MIT Sloan Fellow.</p><h3><a href="https://www.getkahani.com/">Kahani</a> (Pre-Seed)</h3><p><strong>What they’re building:<br></strong>An AI-native eating disorder recovery platform.</p><p><strong>Why it’s compelling:<br></strong>Delivers an always-available, adaptive consumer-grade experience in a historically underserved mental health segment.</p><p><strong>Founder:<br></strong><a href="https://www.linkedin.com/in/mehekmohan/">Mehek Mohan</a>: Stanford GSB grad and former Genentech PM.</p><h3><a href="https://www.hellogoodlabs.com/">Goodlabs</a> (Pre-Seed)</h3><p><strong>What they’re building:<br></strong>Free comprehensive bloodwork in exchange for blood donation.</p><p><strong>Why it’s compelling:<br></strong>Elegantly aligns two massive needs: chronic blood shortages and demand for affordable diagnostics.</p><p><strong>Founder:<br></strong><a href="https://www.linkedin.com/in/grant-brewster-64229a58/">Grant Brewster</a>: former Rippling and Google X ML engineer.</p><h3>Broader Reflections on Consumer AI</h3><p>Spending time in consumer sharpened something I’ve increasingly come to believe:</p><p>Moats in consumer AI are not the model.</p><p>They’re built on:</p><ul><li>Context — Does the product compound user-specific data over time?</li><li>Continuity — Does it persist across sessions, decisions, and workflows?</li><li>Consequences — Is it trusted enough to matter in real outcomes?</li></ul><p>Consumer adoption follows a simple, utilitarian truth: people adopt AI when it helps them do routine tasks better, faster, or cheaper.</p><p>Small daily wins → repeated behavior → habit formation → compounding value.</p><p>The winners won’t just produce smarter answers.</p><p>They’ll:</p><ul><li>Own durable context: e.g., <a href="https://www.grammarly.com/">Grammarly</a> learning writing patterns, <a href="https://www.rocketmoney.com/">Rocket Money</a> understanding spending behavior</li><li>Embed into everyday habits: e.g., <a href="https://blog.duolingo.com/duolingo-max/">Duolingo Max</a>, <a href="https://www.granola.ai/">Granola</a></li><li>Create switching costs through construction: e.g., <a href="https://www.notion.com/product">Notion</a>, <a href="https://cursor.com/">Cursor</a> — systems users build on, not tools they occasionally try</li></ul><p>In both consumer and healthcare, the same pattern holds: the deepest defensibility comes from becoming part of a user’s ongoing life, not their occasional curiosity.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=1b07b6ed5649" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[JPM Healthcare Conference: Initial Reflections]]></title>
            <link>https://medium.com/@zoeylwm/jpm-healthcare-conference-initial-reflections-74e6ba73d446?source=rss-8a3f268f949e------2</link>
            <guid isPermaLink="false">https://medium.com/p/74e6ba73d446</guid>
            <category><![CDATA[biotechnology]]></category>
            <category><![CDATA[cms]]></category>
            <category><![CDATA[health-technology]]></category>
            <category><![CDATA[healthcare]]></category>
            <category><![CDATA[venture-capital]]></category>
            <dc:creator><![CDATA[Zoey Li]]></dc:creator>
            <pubDate>Mon, 19 Jan 2026 02:29:50 GMT</pubDate>
            <atom:updated>2026-04-20T00:10:57.320Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*1m_tdK9dd6Rua-EiOi8tDw.png" /></figure><p><em>These are not comprehensive takeaways from the conference — just my initial observations from being on the ground, listening to conversations, and connecting dots in real time.</em></p><h3>What was everyone talking about?</h3><p>Walking through JPM this year, a few themes came up again and again — across investor meetings, founder coffees, and late‑night side events.</p><p>Not everything was new. But the emphasis felt sharper.</p><p>Below are the topics I heard most frequently — followed by how I’m currently thinking about each.</p><h3>1. Drug discovery is back (in a big way)</h3><p>There was a strong return of enthusiasm around biopharma and drug discovery, particularly at the intersection of AI and biology.</p><p>Many investors I spoke with shared that drug discovery is a major focus area for 2026 and beyond.</p><p>A frequently cited example: <a href="https://www.chaidiscovery.com/">Chai Discovery</a>, which is using AI to design biologics from scratch.</p><p>While biopharma is not my core investing focus, the energy was undeniable. The narrative has shifted from: “AI for discovery is interesting” to “AI‑native drug creation may fundamentally reshape how therapeutics are built.”</p><p>Capital, talent, and technical credibility are clearly flowing back into this category.</p><h3>2. Health features from ChatGPT &amp; Anthropic</h3><p>One area that stayed with me — after multiple conversations — was the rapid emergence of new health-facing features from platforms like ChatGPT and Anthropic.</p><p>What stood out wasn’t model capability.</p><p>At this point, the intelligence itself feels mature. The models are powerful, nuanced, and increasingly reliable.</p><p>Where things begin to break down is everything around the model.</p><p>In practice, people described experiences that felt fragmented:</p><ul><li>Onboarding flows that were difficult to navigate</li><li>Health data integrations that took a long time to sync</li><li>Partial or missing datasets</li><li>Intermittent failures where information simply didn’t load</li></ul><p>Even when insights were generated, they often lacked grounding.</p><p>You might see something like:</p><p>“You have several biomarkers associated with metabolic risk.”</p><p>But without:</p><ul><li>Visibility into the underlying lab values</li><li>Historical trends or baselines</li><li>Clear severity thresholds</li><li>Concrete guidance on what to do next</li></ul><p>The output felt intelligent — yet disconnected from action.</p><p>What this surfaced for me is that AI insight without data fidelity creates false confidence. The summary sounds helpful, but without transparency and context, it’s difficult to trust or operationalize.</p><h4>Why this happens (systemically)</h4><p>Most current health‑AI products follow the same structure:</p><ol><li>Pull data from labs, EHRs, and wearables</li><li>Run interpretation layers on top</li><li>Abstract away raw data to simplify UX</li></ol><p>This works well for:</p><ul><li>Casual users</li><li>High‑level summaries</li><li>One‑off insights</li></ul><p>But it breaks down for:</p><ul><li>Clinicians</li><li>Power users</li><li>Patients managing chronic or complex conditions</li><li>Anyone trying to take real clinical or behavioral action</li></ul><p>Abstraction improves usability — but too much abstraction removes trust, nuance, and clinical usefulness.</p><h4>Zooming out — why this matters</h4><p>Stepping back, this helped clarify something I’ve been circling for a while.</p><p>It’s not that AI in healthcare lacks sophistication.</p><p>If anything, the reasoning layer now feels abundant.</p><p>What’s missing is the connective tissue underneath it.</p><p>We’ve made enormous progress on intelligence — but far less progress on the infrastructure required to make that intelligence usable.</p><p>The model layer is increasingly crowded. Performance differences are narrowing. New releases arrive weekly.</p><p>Meanwhile, the real constraints live below the surface:</p><ul><li>Fragmented data sources</li><li>Inconsistent integrations</li><li>Brittle syncing logic</li><li>Opaque permissioning</li><li>Interpretation layers that strip away clinical context</li></ul><p>Without dependable data flow, even the strongest model becomes limited.</p><p>In healthcare especially, insight is only valuable if it is:</p><ul><li>Traceable back to source data</li><li>Interpretable by humans</li><li>Reliable over time</li><li>Actionable within real workflows</li></ul><p>Until those foundations exist, AI will continue to feel impressive — but not fully trustworthy.</p><h3>3. Clinical AI &amp; the CMS ACCESS moment</h3><p>A third theme that kept surfacing at JPM — sometimes explicitly, sometimes between the lines — was a shift in how people are framing Clinical AI.</p><p>For years, a lot of “AI in healthcare” has lived in narrow boxes: a tool trained for a specific task or deployed in a specific workflow.</p><p>What feels different now is the growing belief that systems will behave less like point solutions and more like ongoing clinical infrastructure — something that sits alongside care teams, runs continuously, and takes responsibility for pieces of clinical work.</p><p>That ambition forces a harder question: <em>if software is going to act like clinical labor, what makes it safe, reimbursable, and dependable over time?</em></p><h4>Why the policy backdrop matters</h4><p>This is where the CMS “plumbing” story becomes very real.</p><p>On one side, CMS is pushing interoperability and workflow modernization through the <a href="https://www.cms.gov/cms-interoperability-and-prior-authorization-final-rule-cms-0057-f">Interoperability and Prior Authorization Final Rule (CMS-0057-F) </a>— including requirements and guidance around APIs (Patient Access, Provider Access, Payer-to-Payer, and prior authorization APIs) designed to make data exchange more standard and less fax-driven.</p><p>On the other side, CMS Innovation Center is testing payment approaches that implicitly assume technology-enabled care can deliver measurable outcomes. In late 2025, CMS announced the <a href="https://www.cms.gov/priorities/innovation/innovation-models/access">ACCESS (Advancing Chronic Care with Effective, Scalable Solutions) Model</a>, which is built around recurring, outcome-aligned payments in Original Medicare for managing common chronic conditions — explicitly designed to support a “technology-enabled care ecosystem.”</p><p>CMS’s own framing is notable: ACCESS is intended to enable tools like AI diagnostics, biomarker-monitoring devices, and workflow software — and because it uses standard billing infrastructure, CMS suggests it could be a template that scales beyond fee-for-service into Medicare Advantage, Medicaid, and commercial models over time.</p><h4>What this implies for Clinical AI</h4><p>Put together, these two forces point in the same direction:</p><ul><li>More computable, accessible data (via standardized APIs and exchange requirements) makes it easier to build clinical systems that are longitudinal and context-aware — not one-off snapshots.</li><li>Payment models that reward outcomes create room for care delivery approaches that rely on continuous monitoring, frequent touchpoints, and automation — rather than reimbursing only discrete visits or procedures.</li></ul><p>To me, the opportunity — and the challenge — is that we can’t treat clinical AI as “a model you deploy.” It starts to look like a <em>system you operate</em>.</p><p>And if that’s the direction we’re heading, the surrounding infrastructure has to evolve too.</p><p>That means building for reliability the same way we do in other mission-critical systems: ongoing validation instead of one-time approval, clear audit trails, environments to test and simulate behavior before deployment, defined accountability within workflows, and reimbursement structures that actually reward better patient outcomes.</p><p>It’s encouraging to see regulators and industry moving toward clearer guardrails and broader data access. But it also raises expectations. In healthcare, being impressive isn’t enough — reliability and trust are the product.</p><h3>Community matters</h3><p>None of these insights would be possible without being in the room.</p><p>Huge thank you to the funds and organizations creating spaces for real conversations:</p><ul><li><a href="https://www.av.co/">ARTIS Ventures</a> TechBio® Connect</li><li><a href="https://hoxtonventures.com/">Hoxton Ventures</a> &amp; <a href="https://tauventures.com/">Tau Ventures</a> JPM Happy Hour</li><li><a href="https://www.mitcnc.org/page/home">MIT &amp; Friends</a> @ JPMorgan Healthcare Innovation Showcase</li><li>Consumer Health, Wellness &amp; Longevity — <a href="https://www.galenai.com/">Galen AI </a>× <a href="https://menlovc.com/">Menlo Ventures</a> × <a href="https://www.rho.co/">Rho</a> × <a href="https://www.mavenventures.com/">Maven Ventures</a></li><li><a href="https://www.kickerventures.com/">Kicker Ventures</a>, <a href="https://www.alphaedison.com/">Alpha Edison</a> &amp; <a href="https://www.joyancepartners.com/">Joyance Partners</a> JPM Happy Hour</li><li>Founders &amp; Pharma Closing Breakfast — <a href="https://www.atria.vc/">Atria Ventures</a> &amp; <a href="https://www.generalcatalyst.com/">General Catalyst</a></li></ul><p>These gatherings are where patterns form.</p><h3>Five founders doing truly interesting work</h3><p>A few founders stood out to me — not just for their ideas, but for how thoughtfully they’re approaching execution.</p><h4><a href="https://www.linkedin.com/in/-havi-/">Havi Nguyen </a>— <a href="https://www.abbycare.org/">Abby Care</a></h4><p>Abby Care helps family members become licensed CNAs (certified nursing assistants) so they can formally care for loved ones with disabilities or special needs — and get paid to do so.</p><p>The model elegantly aligns:</p><ul><li>Workforce shortages</li><li>Quality of care</li><li>Reimbursement economics</li></ul><h4><a href="https://www.linkedin.com/in/jayantparthasarathy/">Jayant Parthasarathy</a> — <a href="https://astrinbio.com/">Astrin Biosciences</a></h4><p>Astrin is building a blood test for early breast cancer detection, specifically for women with dense breast tissue — roughly half of all women.</p><p>Using AI on proteomic data, they’re seeing approximately 3× the sensitivity of mammography in this population.</p><p>A meaningful clinical leap.</p><h4><a href="https://www.linkedin.com/in/virajmehta28/">Viraj Mehta</a> &amp; <a href="https://www.linkedin.com/in/priyanka-shrestha-/">Priyanka Shrestha</a> — <a href="https://www.galenai.com/">Galen AI</a></h4><p>Galen is an AI‑powered personal health companion that pulls together:</p><ul><li>Medical records across hundreds of health systems</li><li>Wearable and consumer health data</li></ul><p>Into one unified view for patients.</p><p>A strong example of consumer‑forward infrastructure done thoughtfully.</p><h4><a href="https://www.linkedin.com/in/lucien-ghislain/">Luc Ghislain</a> — <a href="https://myehealth.app/">Mye Health</a></h4><p>Mye Health is developing remote concussion monitoring through smartphone‑based eye‑movement tracking.</p><p>Their Clinical AI Agent enables:</p><ul><li>Early detection of mTBI</li><li>Continuous recovery monitoring</li><li>Integration of telehealth and evidence‑based pediatric concussion protocols</li></ul><p>All supported by objective brain‑health vital signs.</p><h4><a href="https://www.linkedin.com/in/miroslavgasparek/">Miroslav Gasparek</a> — <a href="https://www.sensible.bio/">Sensible Biotechnologies</a></h4><p>Sensible is building a best‑in‑class platform to design and produce high‑quality mRNA while removing major supply‑chain bottlenecks.</p><p>Their mission: unlock the full potential of mRNA technology to enable the next generation of therapeutics.</p><h3>Final thought</h3><p>My first JPM — and likely not my last.</p><p>It’s noisy and intense, but being in the room helps patterns come into focus.</p><p>Grateful for the conversations and the people who made them happen.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=74e6ba73d446" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Part 3: What Winning Looks Like in Senior Care with a Case Study on Vitalic Health]]></title>
            <link>https://medium.com/@zoeylwm/part-3-what-winning-looks-like-in-senior-care-with-a-case-study-on-vitalic-health-f4b4382b7644?source=rss-8a3f268f949e------2</link>
            <guid isPermaLink="false">https://medium.com/p/f4b4382b7644</guid>
            <category><![CDATA[venture-capital]]></category>
            <category><![CDATA[healthcare]]></category>
            <category><![CDATA[value-based-care]]></category>
            <category><![CDATA[senior-care]]></category>
            <category><![CDATA[mental-health]]></category>
            <dc:creator><![CDATA[Zoey Li]]></dc:creator>
            <pubDate>Fri, 19 Dec 2025 23:09:22 GMT</pubDate>
            <atom:updated>2026-04-25T21:28:50.061Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*VTQVbuTMnKBixZ3z" /></figure><p>In Part 1, I broke down the first two segments transforming senior care:</p><ol><li>Senior living operating systems, and</li><li>Behavioral health, loneliness, and cognitive decline.</li></ol><p>In Part 2, I explored the remaining categories (#3–#6) and the pattern that connects them: senior care is moving out of institutions and into the home — but the infrastructure required to support that shift is still catching up. Much of the venture-scale opportunity sits in that gap.</p><p>In Part 3, I zoom out.</p><p>Here, the focus shifts from <em>what</em> infrastructure is needed to the broader market forces shaping <em>when</em> and <em>how</em> this transition is finally happening. Regulatory pressure, value-based reimbursement, and growing operational strain across payers and senior living operators are actively reshaping incentives and buying behavior.</p><p>I’ll start by unpacking these forces, then outline what “winning” looks like in senior care today — before grounding the framework in a deep-dive case study on Vitalic Health.</p><p>I’m also attaching an updated senior care market map, identifying a few additional players across key categories from recent operator and investor conversations.</p><h3>Regulatory Tailwinds Creating Real Openings</h3><ul><li><strong>Value-Based Care as Default</strong> — More seniors in MA and ACO-REACH means more dollars tied to outcomes → demand for tools that reduce avoidable utilization.</li><li><a href="https://www.notablehealth.com/blog/how-to-successfully-navigate-the-transition-to-cms-hcc-v28-for-risk-adjustment"><strong>CMS V28 Tightening</strong></a> — The new model reduces the ROI of documentation-only strategies and pushes plans toward real clinical interventions that meaningfully affect utilization, frailty, and outcomes — not coding gymnastics.</li><li><strong>AI &amp; Appeals Pressure</strong> — Providers rapidly adopted AI documentation + auto-appeal tools; MA plans slowed by <a href="https://www.webpronews.com/the-1-2-second-rejection-how-algorithms-are-rewriting-the-rules-of-medical-necessity/">backlash over automated denials</a> → demand for transparent, defensible infrastructure.</li><li><strong>PACE Revival</strong> — Backing of Habitat by top VCs and providers is a watershed signal.</li><li><strong>Pressure on Senior Living Operators</strong> — Safety, staffing, and liability concerns drive willingness to adopt new infrastructure.</li></ul><p>That said, this market isn’t without friction. Selling to payers and senior living operators often means long sales cycles, intense scrutiny on outcomes data, and the need to navigate complex procurement and compliance requirements. Companies that can’t demonstrate measurable ROI or that require significant behavior change from staff or residents will struggle. Privacy concerns — especially around video monitoring or data sharing — can also slow adoption if not handled carefully. And finally, competition is heating up. As this category gets more attention, you’ll see more capital flowing in and more startups chasing the same customer base. Winners will be the ones who can move fastest on distribution, build defensible moats through data or network effects, and maintain unit economics that scale.</p><h3>What “Winning” Looks Like in Senior Care</h3><p>The most promising early-stage senior care companies share several defining characteristics:</p><ul><li><strong>Integrated Care Design:</strong> Blending medical, behavioral, and social support within a single delivery model — creating both better outcomes and lower total cost of care.</li><li><strong>Payer-Aligned ROI:</strong> Clear value propositions tied to measurable impact on RAF uplift, utilization reduction, and Star/HEDIS performance — enabling direct contracting with risk-bearing entities.</li><li><strong>Operational Defensibility:</strong> Proprietary care workflows, geriatric-specialized clinician networks, and data-driven engagement platforms that are difficult for payers to replicate in-house.</li><li><strong>Regulatory Leverage:</strong> Built to scale within existing reimbursement pathways (Medicare Advantage, Medicaid LTSS, PACE), turning policy complexity into a structural moat.</li><li><strong>Attractive Unit Economics:</strong> Case- or PMPM-based models achieving &gt;60% gross margins, sub-6-month payback periods, and expanding LTV as cohorts move from episodic to longitudinal engagement.</li><li><strong>Human-Centered Engagement:</strong> Deep trust-building with seniors and caregivers through co-branded outreach, multilingual access, and destigmatized messaging that drives unusually high activation and retention.</li><li><strong>Distribution Efficiency:</strong> B2B2C growth engines — leveraging payers, ACOs, and provider networks — that dramatically lower CAC and enable rapid population-scale deployment.</li></ul><p>In short, the winners in senior care won’t just digitize existing models — they’ll re-architect trust, economics, and experience for how we age.</p><h3>Case Study: Why I’m Watching Vitalic Health Closely</h3><p>To make this concrete, I want to walk through one company in detail — <a href="https://www.vitalichealth.co/">Vitalic Health</a> — and explain why I think they have the potential to be a category winner in geriatric behavioral health.</p><p><strong>Team: Deep Expertise + Operational Clarity</strong></p><p>Vitalic’s leadership brings a rare mix of payer fluency and geriatric behavioral health depth. CEO <a href="https://www.linkedin.com/in/ben-gardner-056730">Ben Gardner</a> positions the company not as “behavioral health” but as a care-gap closure and cost-reduction solution — a framing that lands far better with Medicare Advantage plans. The company emerged from Redesign Health, giving it a strong foundation in operational rigor and go-to-market discipline. The clinical team is intentionally geriatric-specialized, recruited from niche networks like the Geriatric Behavioral Health Association, and supported by growing multilingual capacity (Spanish, Mandarin, Cantonese). This is a team that understands senior-specific needs, payer incentives, and how to build deliberately.</p><p><strong>Market: Large, Growing, and Structurally Underserved</strong></p><p>The opportunity is significant: more than 14M Medicare beneficiaries have behavioral health conditions, yet fewer than half receive treatment. Within the 65+ population, depression and anxiety are common but consistently underdiagnosed and undertreated. Seniors are poorly served by traditional behavioral health models, and payers lack internal solutions capable of proactively engaging this population at scale. As the Baby Boomer cohort ages into Medicare with higher rates of chronic illness, the need — and the TAM — continues to expand.</p><p><strong>Product &amp; Defensibility: Purpose-Built for Seniors</strong></p><p>Vitalic is one of the few platforms intentionally designed for geriatric behavioral health rather than retrofitting an adult model. Seniors rarely self-refer, often minimize symptoms, and frequently present behavioral health issues somatically — as sleep problems, chronic pain, or generalized discomfort. In a 12–15 minute visit, PCPs are not paid, trained, or given the time to unpack whether those complaints reflect anxiety, depression, or loneliness. Stigma compounds the problem: it is far “safer” for seniors to talk about sleep or back pain than to admit emotional distress. The result is widespread under-diagnosis and under-treatment, even among high-risk, high-need patients.</p><p>Vitalic’s engagement model, outreach language, and clinical workflows are built around these realities. Their team starts where seniors actually are — with the surface-level complaints they are willing to discuss — and gradually builds trust. This is why PHQ/GAD scores often rise before they fall: patients become more honest once they feel safe. Vitalic’s approach is designed to capture this hidden burden and convert a population that traditional systems routinely miss.</p><p>Their defensibility comes from several layers:</p><ul><li>A senior-specific engagement playbook that reliably converts a hard-to-engage, low-self-referral population — particularly those whom PCPs struggle to diagnose due to somatic presentation and stigma.</li><li>A proprietary clinical operations platform that tracks outcomes, surfaces high-value diagnoses (e.g., HCC-155), and orchestrates team-based geriatric care.</li><li>Deepening payer integration, validated by results like the 3× expansion with VNS Health and early signals of meaningful reductions in total cost of care (e.g., a 36% cost-of-care reduction in the University of Rochester partnership).</li></ul><p>Once embedded into payer workflows and consistently delivering outcomes, the model becomes extremely difficult to replace.</p><p><strong>Unit Economics: Strong Margins With Clear Leverage Ahead</strong></p><p>Vitalic’s case-rate model supports strong margins and predictable revenue, and its ability to operate at a 70:1 patient-to-provider ratio is a major part of its scalability. Unlike traditional behavioral health models that top out at 20–40:1, Vitalic’s team-based, time-bounded care structure allows each clinician to manage a larger panel without sacrificing quality. The ratio is achievable because the workload is distributed across a coordinated team, psychiatrists provide oversight through high-leverage case reviews rather than 1:1 visits, and care is right-sized — short, targeted sessions within an 8–12 week protocol, supported by a clinical operating system that reduces administrative burden and streamlines escalation.</p><p>As the business scales, the underlying economics should strengthen meaningfully:</p><ul><li>CAC should decline as referrals grow and existing plans expand.</li><li>LTV should increase as multi-year payer relationships deepen and patients re-engage for additional episodes.</li><li>A 5:1+ LTV:CAC in the next 18–24 months is a realistic trajectory given early traction and demonstrated payer ROI.</li></ul><p>This combination — scalable clinical operations and improving acquisition and retention dynamics — creates a clear path to durable, capital-efficient growth.</p><h3>Closing Thoughts</h3><p>We’re entering a once-in-a-generation moment in senior care:</p><ul><li>Demographics = unavoidable</li><li>Economics = shifting to value</li><li>Technology = finally catching up</li><li>Incentives = aligned for real interventions</li></ul><p>The founders making the biggest impact aren’t building point solutions — they’re rebuilding the infrastructure of aging. Whether it’s Inspiren redefining the operating system for senior living, Vitalic setting a new standard in geriatric behavioral health, or Habitat Health scaling PACE to underserved communities, these companies are laying the foundation for how care will work for the next several decades.</p><p>For founders, this is an opportunity to build businesses that are both high-impact and high-scale. For investors, it’s one of the most compelling, overlooked frontiers in healthcare. And for families — mine included — the upside is personal.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=f4b4382b7644" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Medicare Advantage, Medicaid, Epic, and Platform Competition]]></title>
            <link>https://medium.com/@zoeylwm/medicare-advantage-medicaid-epic-and-platform-competition-0b819c6b776c?source=rss-8a3f268f949e------2</link>
            <guid isPermaLink="false">https://medium.com/p/0b819c6b776c</guid>
            <dc:creator><![CDATA[Zoey Li]]></dc:creator>
            <pubDate>Wed, 17 Dec 2025 20:43:23 GMT</pubDate>
            <atom:updated>2026-04-26T19:15:55.275Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/725/0*hySR6JAAKPRvUUy_" /></figure><p>The final part of our conversation turned to two forces shaping healthcare more quietly — but perhaps more meaningfully — than any short-term hype cycle: government programs (MA and Medicaid) and platform incumbents (Epic).</p><p>This was the portion of the panel where I found myself taking the most notes.</p><h3>VI. Medicare Advantage &amp; Medicaid: Two Very Different Weather Systems</h3><p>Medicare Advantage has long been the power center of value-based care, but today it’s experiencing something of a reset. <a href="https://www.ama-assn.org/practice-management/medicare-medicaid/what-expect-2026-medicare-physician-fee-schedule">Rate cuts</a> have brought margins down sharply, <a href="https://www.kff.org/health-costs/what-are-the-trends-in-health-utilization-and-spending-in-early-2024/#:~:text=Recent%20trends%20in%20healthcare%20utilization,of%20the%20U.S.%20health%20system.">utilization is unpredictable</a>, and many provider-enablement companies are “hunkering down” and shifting temporarily toward <a href="https://www.cms.gov/medicare/payment/fee-for-service-providers/shared-savings-program-ssp-acos">Medicare Shared Savings Program</a> (MSSP).</p><p>One theme emerged: the next generation of MA companies must genuinely manage medical cost — risk adjustment alone isn’t enough.</p><p>On the Medicaid side, the message was even clearer: it may not normalize for years. <a href="https://www.gao.gov/products/gao-25-107413">Redeterminations</a>, <a href="https://www.macpac.gov/publication/understanding-medicaid-managed-care-procurement-practices-across-states/">contracting issues</a>, and <a href="https://www.neimanhpi.org/policy-briefs/medicaid-reimbursement-is-not-keeping-pace-with-medicare/">rate pressure</a> have made new companies cautious. Yet the upside remains enormous for teams with real expertise. The story of <a href="https://www.carebridgehealth.com/">CareBridge</a> — scaling rapidly in Long-term Services and Supports (LTSS) and Home- and Community-Based Services (HCBS) — reminded me how powerful deep understanding of Medicaid incentives can be.</p><h3>VII. Epic, AI Scribes &amp; The Platform Chessboard</h3><p>We closed with a discussion on Epic that was refreshingly candid.</p><p>The investors described Epic’s strategy this way: let a category mature externally, then enter with a 60% solution that wins through distribution, not depth. Their <a href="https://www.fiercehealthcare.com/health-tech/epic-unveils-major-ai-features-ai-charting-microsoft-cosmos-ai-risk-prediction-and-rcm">native AI scribe</a>, built with Microsoft, is a perfect example. Even before full rollout, it has already frozen parts of the scribe market simply by existing.</p><p>And yet, the nuance matters:</p><ul><li>Epic’s tools commoditize quickly.</li><li>Innovators are still ahead in decision support, coding, rev cycle, and denials.</li><li>Epic rarely acquires, which limits exit paths.</li></ul><p>A useful way to frame it: “Epic owns the center line, but startups can own the curves.”</p><p>Startups win when they go deeper — into specialties, smarter workflows, automation, and infrastructure layers that aren’t core to Epic’s roadmap.</p><p>Interestingly, the bigger existential question now is <a href="https://openai.com/solutions/healthcare/">OpenAI</a>. Several investors admitted they are more concerned about OpenAI than Epic — partly because OpenAI <em>can</em> acquire companies, and partly because healthcare is simply too large a GDP segment for them to ignore.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=0b819c6b776c" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Insurance Premium Crisis, Employer Benefits, and the Realities of Value-Based Care]]></title>
            <link>https://medium.com/@zoeylwm/insurance-premium-crisis-employer-benefits-and-the-realities-of-value-based-care-216958861e78?source=rss-8a3f268f949e------2</link>
            <guid isPermaLink="false">https://medium.com/p/216958861e78</guid>
            <category><![CDATA[digital-health]]></category>
            <category><![CDATA[employee-benefits]]></category>
            <category><![CDATA[healthcare]]></category>
            <category><![CDATA[venture-capital]]></category>
            <category><![CDATA[value-based-care]]></category>
            <dc:creator><![CDATA[Zoey Li]]></dc:creator>
            <pubDate>Mon, 15 Dec 2025 22:10:33 GMT</pubDate>
            <atom:updated>2025-12-15T22:10:33.656Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/853/1*GlnAkP646pT-NxDcVCOQdQ.jpeg" /></figure><p>For the second part of our panel, we zoomed in on one of the biggest structural realities in the U.S. healthcare system today: insurance premiums rising 8–10% year after year. Employers have reached their limit. Employees are absorbing more cost. And startups are racing to build tools that make benefits more transparent, predictable, and affordable.</p><p>What I appreciated in this conversation was how nuanced the panelists were about employer incentives — something I’ve increasingly seen in my own work.</p><h3>IV. Understanding the Insurance Premium Crisis</h3><p>The panelists framed the premium crisis not as a temporary pressure point but a long-term sustainability issue. Employers are responding in predictable ways — narrower networks, higher deductibles, shifting care to cheaper settings — but these strategies ultimately push risk onto employees and often worsen outcomes.</p><p>We discussed the rise of startups building tools for the employer market:</p><ul><li>Companies rebuilding self-funded plan infrastructure</li><li>Platforms driving transparency and dynamic plan design</li><li>Navigation models with clear incentives</li><li>Backend infrastructure powering ICHRA ecosystems</li></ul><p>The employer market is splintering into three distinct realities:</p><ol><li>Elite employers will continue paying for GLP-1s, concierge care, and preventive drugs because talent is their product.</li><li>Mid-market employers are beginning to shift toward ICHRA or more flexible models.</li><li>Small employers may fully embrace ICHRA because volatility is unmanageable with traditional plans.</li></ol><p>Another important point the panel made: the employer-health insurance link is deeply entrenched. Even with innovation, we’re not unwinding that relationship anytime soon. One reason this link is so hard to unwind is historical. During World War II, wage controls prevented companies from raising salaries, so employers began offering health insurance as a way to attract workers. The federal government then reinforced this by making employer-paid premiums tax-deductible and excluding them from employees’ taxable income — effectively locking in employer-sponsored insurance as the default system. Coverage expanded rapidly, from roughly 10% of Americans in the early 1940s to around 80% by the mid-1960s, when Medicare and Medicaid were created to cover those outside the workforce.</p><p>The lasting implication is that most patients rarely experience the true cost of care directly. Prices are filtered through employers, insurers, or government programs, which helps explain why healthcare spending in the U.S. has climbed to ~18% of GDP — far higher than peer systems like the U.K. or Singapore.</p><h3>V. Value-Based Care: What’s Real and What’s Not</h3><p>If part one of the panel felt pragmatic, part two felt philosophical. The consensus was refreshingly grounded: value-based care (or “value-aligned care”) is not dead — but the naïve version of VBC absolutely is.</p><p>A few insights that stuck with me:</p><ul><li>True full-risk models require deep operational, clinical, and data expertise.</li><li>Many conditions simply don’t have the data flows needed to support full capitation.</li><li>Fee-for-service is not inherently bad; it’s often the only viable on-ramp.</li><li>The best companies flex their payment models over time.</li></ul><p>One line I keep coming back to: “companies cannot have good gross margins under pure fee-for-service.”</p><p>That’s the core tension. Payers want financial accountability, but providers and startups can’t overhaul their operations for short-term CMS pilots. Flexibility — not dogma — is what works.</p><p>We also discussed where VBC is working today: eating disorder care (<a href="https://equip.health/eating-disorder-tx?utm_source=google&amp;utm_medium=cpc&amp;utm_campaign=Branded&amp;utm_adgroup=Brand-Name&amp;utm_id=go_cmp-15186574479_adg-140395237653_ad-772430177914_kwd-437646481390_dev-c_ext-_prd-_sig-Cj0KCQiAgP_JBhD-ARIsANpEMxxxlksE1eSqiIjwW_pr4I6K1PPNwiO4VsFkY3iPerisxKQTL0HviDoaAv61EALw_wcB&amp;gad_source=1&amp;gad_campaignid=15186574479&amp;gbraid=0AAAAABkC84rUSEPIrY_xUi6zi2XBpYaeX&amp;gclid=Cj0KCQiAgP_JBhD-ARIsANpEMxxxlksE1eSqiIjwW_pr4I6K1PPNwiO4VsFkY3iPerisxKQTL0HviDoaAv61EALw_wcB">Equip Health</a>), pediatric OCD/anxiety (<a href="https://www.instride.health/?utm_term=instride%20health&amp;utm_id=169614851895&amp;utm_campaign=21839051177&amp;utm_source=adwords&amp;utm_medium=ppc&amp;device=c&amp;matchtype=e&amp;gad_source=1&amp;gad_campaignid=21839051177&amp;gbraid=0AAAAAp_o6OVkp0-UFX-97hPjpXOxeIwsH&amp;gclid=Cj0KCQiAgP_JBhD-ARIsANpEMxzJcu1zrmMk3HeKbnT8SqEOXBk0a0jFbSJ7IlTjslNDeroBE6Q5U3oaAtYMEALw_wcB">Instride Health</a>), specialty surgical networks (<a href="https://oathsurgical.com/">Oath Surgical</a>). These companies stay incredibly tight on acuity, attribution, and outcomes — three things that broad “VBC platforms” often lack.</p><p>My takeaway? We’re moving toward value-based care, but the winners will be the ones who build practically, not ideologically.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=216958861e78" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Part 2: Where Senior Care Is Actually Headed and the Infrastructure Being Built Behind the Scenes]]></title>
            <link>https://medium.com/@zoeylwm/part-2-where-senior-care-is-actually-headed-and-the-infrastructure-being-built-behind-the-scenes-8f12ce3ba2e6?source=rss-8a3f268f949e------2</link>
            <guid isPermaLink="false">https://medium.com/p/8f12ce3ba2e6</guid>
            <category><![CDATA[caregiving]]></category>
            <category><![CDATA[senior-care]]></category>
            <category><![CDATA[healthcare]]></category>
            <category><![CDATA[geriatrics]]></category>
            <category><![CDATA[venture-capital]]></category>
            <dc:creator><![CDATA[Zoey Li]]></dc:creator>
            <pubDate>Fri, 12 Dec 2025 18:33:05 GMT</pubDate>
            <atom:updated>2026-04-26T20:08:27.382Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*gNVQ5bDC7_xcGmUKjaAj4g.jpeg" /></figure><p>In Part 1, I broke down the first two segments transforming senior care:</p><ol><li>Senior living operating systems, and</li><li>Behavioral health, loneliness, and cognitive decline.</li></ol><p>Today, in Part 2, I’m diving into the remaining categories (#3–#6). Across all four of these, a pattern emerges: senior care is shifting out of institutions and into the home — but the infrastructure underneath that shift is still being built. And that’s where a meaningful amount of venture-scale opportunity lives.</p><p>These categories are less about “new point solutions” and more about the technical, clinical, and operational backbone required to make home-based care actually work.</p><h3>(3) PACE &amp; Integrated Home-Based Care</h3><p><a href="https://www.cms.gov/medicare/medicaid-coordination/about/pace">PACE (Program of All-inclusive Care for the Elderly)</a> is a capitated model delivering wraparound medical + social services to low-income seniors who qualify for nursing-home level care but want to remain in their communities. It is widely viewed as the “gold standard” for community-based integrated care, yet adoption has historically been slow due to operational complexity, capital intensity, and state-by-state regulatory variability.</p><p><strong>Example: </strong><a href="https://www.habitathealth.com/"><strong>Habitat Health</strong></a><strong> (Series A), </strong><a href="https://www.seenhealth.org/"><strong>Seen Health</strong></a><strong> (Series A), </strong><a href="https://welbehealth.com/"><strong>Welbe Health</strong></a><strong> (Series D)</strong></p><p><a href="https://www.habitathealth.com/">Habitat Health </a>was launched by Town Hall Ventures and Kaiser Permanente specifically to scale PACE in underserved communities. They opened their <a href="https://www.linkedin.com/posts/kaiser-permanente_habitat-health-with-kaiser-permanente-opens-activity-7280676503506362369-uNl3">first PACE center in early 2025</a> after securing $50M from Town Hall, NEA, and Kaiser, with plans to expand nationally. What stands out is the team: <a href="https://www.linkedin.com/in/matthew-bennett-667b881/">Matthew Bennett</a> (former SVP at Cigna Evernorth), <a href="https://www.linkedin.com/in/geoffmprice/">Geoff Price</a> (co-founder/COO of Oak Street Health), and <a href="https://www.linkedin.com/in/vinay-mascarenhas-708b955/">Vinay Mascarenhas </a>(co-founder/CSO of Landmark Health). They’re taking the playbook from successful value-based primary care models and applying it to the PACE structure, where clinical outcomes, member experience, and cost management are tightly coupled.</p><p><strong>Why this matters: </strong>PACE serves a high-need, high-cost population (average age ~76, multiple chronic conditions, and most living in the community despite nursing-home-level acuity). When it works well, it keeps people out of institutions, improves quality of life, and lowers avoidable hospital use — which is why the economics make sense and why there’s room for more programs across the country.</p><p>At the same time, most of the recent growth is happening in states with <a href="https://calpace.org/wp-content/uploads/2017/12/PACE-Modernization-Act-amendments-TBL-1-30-19.pdf">more favorable reimbursement </a>and in communities with a <a href="https://www.kff.org/medicaid/5-key-facts-about-medicaid-coverage-for-people-living-in-rural-areas/">high share of Medicaid-eligible seniors</a>. That makes expansion possible, but it also raises questions going forward: Can the model scale in a consistent way across different states? Will reimbursement stay stable? And can new operators grow without losing the team-based, hands-on care that makes PACE effective in the first place? Habitat’s team seems well-positioned, but these are the dynamics that will shape how the category evolves.</p><h3>(4) Medicare Advantage Enablement</h3><p>Regional and midsize plans increasingly want to compete in MA and <a href="https://www.cms.gov/medicare/enrollment-renewal/special-needs-plans/dual-eligible">D-SNP</a>, but most lack the full-stack infrastructure required to launch and operate a competitive product. Standing up an MA plan requires capabilities across bid strategy, risk adjustment, care management, utilization management, network development, Stars performance, and member engagement — areas where national plans have decades of advantage. Earlier tech-enabled insurers like <a href="https://www.hioscar.com/">Oscar</a> and <a href="https://www.cloverhealth.com/">Clover</a> showed that modern infrastructure and more consumer-centric design could reshape how plans operate, but they pursued a full-stack insurer strategy rather than enabling existing regional plans. Their experience underscored how challenging it is to build these capabilities internally — reinforcing the need for a new category of MA enablement platforms that provide the technical, clinical, and operational backbone smaller plans need to enter or scale in MA.</p><p><strong>Examples: </strong><a href="https://belong-health.com/"><strong>Belong Health</strong></a><strong> (Series B), </strong><a href="https://www.devoted.com/"><strong>Devoted Health</strong></a><strong> (Series F)</strong></p><p><a href="https://belong-health.com/">Belong Health</a> offers MA-as-a-Service: tech infrastructure, risk adjustment, care management, network buildout, Stars improvement, and virtual/community-based transitional care. Their partnership with MVP Health has shown early signals of reduced admissions and strong member growth, demonstrating how enablement can help regional plans compete with national players.</p><p><a href="https://www.devoted.com/">Devoted Health</a> is a vertically integrated MA plan operator — less “enablement” and more full-stack competition — but demonstrates the appetite for tech-enabled, next-generation MA models.</p><p><strong>Why this matters: </strong>National MA enrollment is flattening, but regional and community plans are growing fast — and they want to compete in MA and D-SNP. The problem: most don’t have the tech, risk, <a href="https://www.fiercehealthcare.com/regulatory/cms-proposes-significant-overhauls-medicare-advantage-star-ratings-metrics">Stars</a>, or care-management infrastructure to run a competitive plan. Enablement platforms fill that gap. If they can lift Stars, reduce avoidable utilization, and support membership growth, they become sticky, high-margin partners. And as MA margins tighten and CMS cracks down on risk adjustment, plans need real medical-cost management — not just better coding. That shift creates a durable, expanding market for MA-enablement companies.</p><h3>(5) Caregiver Support &amp; Patient Navigation</h3><p>Caregiver support is a large and chronically underserved market: 53 million Americans provide unpaid care to aging family members, and 61% also work full-time. The strain shows up everywhere — employer absenteeism, turnover, burnout, and increased medical spend for both caregivers and the people they support.</p><p>The first wave of caregiver platforms (<a href="https://www.honorcare.com/">Honor</a>, <a href="https://www.papa.com/">Papa</a>) raised huge rounds, but many came back down to earth. Marketplace caregiver-matching proved high-risk and hard to scale — issues around safety, vetting, churn, low margins, and inconsistent quality damaged trust in the category.</p><p>At the same time, interest in “patient advocacy” and care-coordination platforms has grown meaningfully, with companies like <a href="https://www.solace.health/">Solace Health</a> helping bring visibility to how much families value support navigating medical and social needs. Solace’s rapid rise also highlights how operationally complex this category can be: defining the right clinical boundaries, ensuring consistent handoffs, and maintaining quality at scale are challenging for any company moving quickly in a space that sits between healthcare and consumer services. The demand is clear — and the experience of early entrants underscores how important strong operations, clinical guardrails, and sustainable workflows will be for the next generation of platforms.</p><p><strong>Examples:</strong></p><ul><li><strong>Established: </strong><a href="https://homethrive.com/"><strong>Homethrive</strong></a><strong> (Series B), </strong><a href="https://wellthy.com/backup-care?utm_source=google&amp;utm_medium=paid_search&amp;utm_campaign=2025_backupcare&amp;utm_content=20250502&amp;utm_term=brand&amp;utm_term=wellthy&amp;utm_campaign=Search+%7C+Backup+Care&amp;utm_source=adwords&amp;utm_medium=ppc&amp;hsa_acc=8471258759&amp;hsa_cam=22511866783&amp;hsa_grp=187466265068&amp;hsa_ad=750180818579&amp;hsa_src=g&amp;hsa_tgt=kwd-342330364775&amp;hsa_kw=wellthy&amp;hsa_mt=e&amp;hsa_net=adwords&amp;hsa_ver=3&amp;gad_source=1&amp;gad_campaignid=22511866783&amp;gbraid=0AAAAADhTncq_pNh6xfwbo91sN-bVXuy8l&amp;gclid=CjwKCAiAraXJBhBJEiwAjz7MZQJ2t_fzwNtn2S2K2_hKc6hO8_ZlSRFV4Y-liWSLw0FvRrROCV4gZRoCm9kQAvD_BwE"><strong>Wellthy</strong></a><strong> (Series B), </strong><a href="https://www.widercircle.com/"><strong>Wider Circle</strong></a><strong> (Series B), </strong><a href="https://www.getduos.com/"><strong>Duos</strong></a><strong> (Series B), </strong><a href="https://cariloop.com/"><strong>Cariloop</strong></a><strong> (Series C)</strong></li><li><strong>Emerging: </strong><a href="https://understoodcare.com/"><strong>Understood Care</strong></a><strong> (Pre-Seed), </strong><a href="https://www.mellie.com/"><strong>Mellie</strong></a><strong> (Pre-Seed), </strong><a href="https://www.pocketrn.com/"><strong>PocketRN</strong></a><strong> (Seed), </strong><a href="https://ianacare.com/"><strong>IanaCare</strong></a><strong> (Series A), </strong><a href="https://www.avanleecare.com/"><strong>Avanlee Care</strong></a><strong> (Series A), </strong><a href="https://carallel.com/"><strong>Carallel</strong></a><strong> (Series A), </strong><a href="https://www.ceresti.com/"><strong>Ceresti</strong></a><strong> (Seed), </strong><a href="https://www.family-first.com/"><strong>Family First</strong></a><strong> (Series A), </strong><a href="https://www.tcare.ai/"><strong>TCARE</strong></a><strong> (Series A), </strong><a href="https://trytendercare.com/"><strong>Tendercare</strong></a><strong> (Series A)</strong></li></ul><p><a href="https://homethrive.com/">Homethrive</a> supports these working caregivers with 24/7 on-demand resources and 1:1 guidance from expert Care Guides (typically social workers or care managers). Their model blends AI-assisted navigation with high-touch human support, helping families manage appointments, benefits, logistics, and the day-to-day challenges that sit outside the traditional healthcare system. What differentiates Homethrive from the first wave of caregiver startups is the shift away from marketplace-based caregiver labor — which often struggled with thin margins and uneven quality — toward structured, clinically informed navigation with predictable workflows and clear boundaries. This model scales more efficiently, delivers more consistent support, and aligns cleanly with payer and employer incentives. <a href="https://www.prnewswire.com/news-releases/homethrive-raises-20m-in-latest-funding-round-led-by-telus-global-ventures-and-7wireventures-302305001.html">Traction</a> reflects this model shift:</p><ul><li>Raised $20M from TELUS Global Ventures and 7wireVentures (Nov 2024)</li><li>4× growth since 2022</li><li>8.4% utilization, best-in-class for voluntary benefits</li><li>80% reduction in turnover among caregiving employees</li><li>Saves caregivers 16+ hours per month</li><li>Payers see a 17% increase in retention</li></ul><p>The core insight: caregivers don’t pay — employers and health plans do. By positioning as a productivity, retention, and cost-savings solution (not a wellness perk), Homethrive has created a far more scalable and investable model than earlier marketplace-first caregiver startups.</p><p><strong>Why this matters: </strong>Care needs are shifting into the home, and family caregivers are carrying more of the load. Solutions that reduce burnout, simplify navigation, and show clear ROI for employers and payers are well-positioned. The key is execution. Investors will look for real engagement, measurable outcomes, and strong operational and clinical discipline. Marketplace-heavy or loosely structured “advocacy” models are hard to scale, but platforms that pair navigation with behavioral support and align directly with payer and employer incentives can build durable, defensible businesses in a very large market.</p><h3>(6) Home Health Clinical &amp; RCM Infrastructure</h3><p>Post-acute care is often treated as a single category, but it spans multiple distinct settings — home care (non-medical support), home health (skilled clinical care), SNFs (high-acuity rehab &amp; long-term nursing), CCRCs (full-continuum senior campuses), hospice (end-of-life), palliative care (serious-illness symptom relief), and the broad “supportive care” in between.</p><p>Within this landscape, home health stands out as the segment with the strongest tailwinds: aging boomers, rising multi-chronic conditions, and a major shift of clinical care into the home. Home health agencies operate on razor-thin margins, depend on complex documentation (OASIS, ICD-10 coding), and are paid under <a href="https://amplifyot.com/what-is-pdgm-in-home-health/">PDGM</a> where reimbursement is tied to documentation accuracy, not visit volume. This creates an acute need for AI-native infrastructure that can reduce RN administrative burden, improve coding precision, accelerate cash flow, and lift reimbursement. As legacy EHR systems struggle to keep up, a new layer of AI-driven RCM and documentation tooling is emerging.</p><p><strong>Examples: </strong><a href="https://zingage.com/"><strong>Zingage</strong></a><strong> (Seed), </strong><a href="https://www.ollihomehealth.ai/"><strong>Olli Health</strong></a><strong> (Series A), </strong><a href="https://www.healthrecoverysolutions.com/"><strong>Health Recovery Solutions</strong></a><strong> (Series C)</strong></p><p><a href="https://www.ollihomehealth.ai/">Olli</a> is rebuilding the core workflow that determines whether home health agencies get paid. Instead of generic “AI scribing,” the platform compresses the entire pathway from point-of-care → documentation → ICD-10 coding → OASIS logic → quality review → claim submission. The team deliberately targeted home health because PDGM makes accuracy the driver of reimbursement — even small coding or OASIS errors can meaningfully reduce payment. Agencies run on 5–7% margins, so gains in documentation speed, QA efficiency, and coding precision translate directly into financial lift. Olli differentiates through an AI-native architecture, real-time OASIS guidance, high-precision coding automation, and integrations across major EHRs (HCHB, MatrixCare, WellSky, AlayaCare), positioning it as the horizontal infrastructure layer agencies rely on.</p><p><strong>Why this matters: </strong>Care is shifting into the home, but home health agencies are stretched thin — rising acuity, heavy documentation, tight margins, and not enough clinical staff. Tools that improve documentation accuracy, speed up reimbursement, and reduce RN admin work address pain points that hit daily operations and cash flow. The solutions that win here will be the ones that slot cleanly into existing EHR workflows and reliably help agencies get paid correctly with less effort. If a platform can reclaim clinician time and lift reimbursement even a few percentage points, it quickly becomes indispensable in a sector growing this fast.</p><h3>Coming Up Next</h3><p>In Part 3, I’ll zoom out and explore the macro forces creating real openings in senior care, including:</p><ul><li>Regulatory tailwinds (V28 tightening, VBC expansion, PACE momentum)</li><li>Pressure on MA plans, providers, and senior living operators to modernize</li><li>The shift from documentation-only tactics toward real clinical intervention</li><li>The growing need for transparent, defensible AI infrastructure</li></ul><p>And I’ll break down what these dynamics reveal about the kinds of companies that are best positioned to win — along with a deep-dive case study on Vitalic Health.</p><p>→ <strong>To be continued in Part 3…</strong></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=8f12ce3ba2e6" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Market State, Investment Outlook & Where Digital Health Is Going Next]]></title>
            <link>https://medium.com/@zoeylwm/market-state-investment-outlook-where-digital-health-is-going-next-1ccca4fab42e?source=rss-8a3f268f949e------2</link>
            <guid isPermaLink="false">https://medium.com/p/1ccca4fab42e</guid>
            <category><![CDATA[venture-capital]]></category>
            <category><![CDATA[healthcare]]></category>
            <category><![CDATA[digital-health]]></category>
            <dc:creator><![CDATA[Zoey Li]]></dc:creator>
            <pubDate>Thu, 11 Dec 2025 22:11:20 GMT</pubDate>
            <atom:updated>2026-04-26T19:47:32.438Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/750/1*-f4MopVxsq53bIxYS-Y1AA.png" /></figure><p>Last month, I had the chance to host five incredibly thoughtful investors for a conversation on where digital health is — and where it’s heading. One theme came up again and again: we’re in a moment that feels less like the post-COVID boom and more like the dot-com era — a period full of noise, hype, and capital misallocation, but also the early formation of generational companies.</p><h3>I. Market State &amp; The Two-Tiered Reality</h3><p>The first part of our discussion focused on the broader environment. Investors noted that the market is increasingly bifurcated. On one side, you have AI, D2C health, and longevity platforms raising at eye-watering valuations. On the other, companies working inside the “messy” parts of healthcare — reimbursement friction, specialty care economics, employer cost pressure — are trading at more sober multiples.</p><p>What struck me most was how candid the panelists were about the mispricing of AI. Several shared examples of companies with ~$5M in revenue receiving ~$1B valuations, driven largely by generalist funds that have incentives to “swing big” on AI. Healthcare-only funds are behaving differently, because the math of their portfolios requires more consistent outcomes.</p><p>But the underlying tension is real: AI is clearly transformative, yet the path to defensibility and real-world ROI remains much harder in healthcare than in other sectors. As one panelist put it, healthcare AI is investable eventually — but right now, it’s unproven in all the places where the dollars actually flow.</p><p>And then there’s <a href="https://3bhealthcare.us/ai-in-healthcare-openai-innovation-2025/">OpenAI entering healthcare directly</a>, which adds a mix of excitement and unease.</p><h3>II. What Opportunities Still Feel Real?</h3><p>Despite the headwinds and the noise, there was strong alignment around where the true opportunities are emerging.</p><h4>1. Cost containment as the dominant near-term thesis</h4><p>Every investor agreed: no new money is coming into the healthcare system. Costs are rising, margins are compressing, and employers, payers, and providers are all feeling pressure simultaneously — something that hasn’t happened in past crises. This creates openings for companies addressing root-cause drivers of spend: high-cost chronic conditions, specialty drug costs, staffing shortages, and inefficient workflows.</p><p>This explains the momentum behind companies like <a href="https://www.heartbeathealth.com/">Heartbeat Health</a>, <a href="https://www.carebridgehealth.com/">CareBridge</a>, and <a href="https://heydianahealth.com/">Diana Health</a>, which redesign care delivery for expensive populations.</p><h4>2. Specialty care and labor leverage</h4><p>The system simply doesn’t have enough specialists, and the training pipeline won’t solve this anytime soon. Investors highlighted models that wrap services around existing specialists, shift longitudinal care to primary care or advanced practice clinicians, and use automation for operational burden.</p><h4>3. Commercial innovation — especially for small and mid-sized employers</h4><p>With government programs facing policy volatility, many VCs see clearer opportunities in the commercial market. Pricing transparency, dynamic plan design, and benefit flexibility — think <a href="https://www.helmhealth.com/">Helm</a>, <a href="https://www.getgarner.com/">Garner</a>, and <a href="https://www.lynx-fh.com/">Lynx</a> — are gaining traction.</p><h4>4. More fundable than “value-based everything”: focused, high-acuity models</h4><p>Condition-specific and specialty-specific platforms are getting more attention because they show in-year ROI, have clearer attribution, and avoid overly broad “VBC for everyone” positioning. What became clear to me is that the next wave of transformational companies in digital health will be both focus-driven and infrastructure-enabled.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=1ccca4fab42e" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[The Senior Care Opportunity: Re-Architecting the Infrastructure for 10,000 Americans Turning 65…]]></title>
            <link>https://medium.com/@zoeylwm/the-senior-care-opportunity-re-architecting-the-infrastructure-for-10-000-americans-turning-65-7ef3dd155870?source=rss-8a3f268f949e------2</link>
            <guid isPermaLink="false">https://medium.com/p/7ef3dd155870</guid>
            <category><![CDATA[venture-capital]]></category>
            <category><![CDATA[behavorial-health]]></category>
            <category><![CDATA[geriatrics]]></category>
            <category><![CDATA[senior-care]]></category>
            <category><![CDATA[dementia-care]]></category>
            <dc:creator><![CDATA[Zoey Li]]></dc:creator>
            <pubDate>Fri, 05 Dec 2025 20:44:23 GMT</pubDate>
            <atom:updated>2026-04-25T21:25:54.369Z</atom:updated>
            <content:encoded><![CDATA[<h3>The Senior Care Opportunity: Re-Architecting the Infrastructure for 10,000 Americans Turning 65 Every Day</h3><figure><img alt="" src="https://cdn-images-1.medium.com/max/679/0*o_ARuk-fNjhbhXXM" /></figure><p>When I think about aging, I don’t start with a market map — I start with my grandfather. He went through two major depressive episodes almost a decade apart. The second was devastating: he withdrew completely, stayed in his room for months, kept the windows shut, and stopped going outside. A severe lung infection followed, and my family was suddenly scrambling as caregivers with almost no guidance or support.</p><p>It shocked me how quickly things unraveled, how hard it was for my family to fully grasp what was happening, and how little support existed for his caregivers. And in every conversation I have now — with friends, classmates, colleagues — I hear versions of the same story. Behavioral health challenges are common, caregiving is overwhelming, and most of us are stunned by how hard it really is.</p><p>This personal lens, along with some professional experiences, has shaped my interest in senior care — and the timing couldn’t be more relevant. In October, <a href="https://www.cedars-sinai.org/newsroom/cedars-sinai-launches-healthy-aging-clinic/">Cedars-Sinai launched a new Healthspan Clinic</a>, grounded in geroscience, to prevent age-related decline before it begins. It signals a broader shift: our existing infrastructure for aging is breaking, and leading systems know it.</p><p>This thesis explores where the system is cracking or broken, why incentives are realigning, and six categories of startups that represent meaningful venture-scale opportunities — including one category in particular where I believe we’ll see some of the most compelling innovation: geriatric behavioral and cognitive health.</p><h3>The Demographics Are Inevitable — The Systems Are Not</h3><p>By 2030, <em>every Baby Boomer will be 65+</em>. The U.S. senior population will rise from 58M today to ~95M by 2060. But the real issue isn’t so much scale as it is acuity:</p><ul><li>Multiple chronic conditions</li><li>Rising behavioral health needs</li><li>Care requirements that spill across medical, social, and functional domains</li></ul><p>Traditional health systems — built for episodic acute care — are structurally unequipped for this complexity.</p><p>And the economics have shifted:</p><ul><li><a href="https://www.homehealthsection.org/index.php?option=com_content&amp;view=article&amp;id=1046:medicare-advantage-enrollment-officially-crosses-50--of-beneficiaries--kff&amp;catid=23:in-the-news&amp;Itemid=163#:~:text=Medicare%20Advantage%20Enrollment%20Officially%20Crosses,traditional%20Medicare%20without%20supplemental%20coverage.%22">Medicare Advantage penetration</a> has crossed 50%.</li><li>Risk-bearing entities (MA plans, ACOs, IDNs) now control more senior lives.</li><li><a href="https://www.notablehealth.com/blog/how-to-successfully-navigate-the-transition-to-cms-hcc-v28-for-risk-adjustment">CMS’s V28 risk adjustment model</a> tightened revenue opportunities from documentation, pushing plans toward <em>actual</em> clinical interventions.</li><li>Senior living operators face staffing shortages, acuity spikes, rising labor costs, and regulatory pressure.</li><li>Home health and post-acute care remain fragmented and under-digitized.</li></ul><p>This creates a rare opportunity: when legacy infrastructure fails and payment incentives realign, entirely new platforms can emerge.</p><h3>Six Categories Worth Watching</h3><p>Below are six segments where I’m seeing the most compelling early-stage activity — and where durable companies can be built.</p><h3>(1) Senior Living Operating Systems</h3><p>These are companies building the full-stack operating system for how senior living communities actually run day-to-day. Think: AI-powered sensing, staff coordination, real-time visibility into resident health, and emergency response — all integrated into one platform.</p><p><strong>Examples:</strong><a href="https://www.inspiren.com/"><strong> Inspiren</strong></a><strong> (Series B),</strong><a href="https://www.augusthealth.com/"><strong> August Health</strong></a><strong> (Series B)</strong></p><p><a href="https://www.inspiren.com/">Inspiren</a> started with best-in-class fall detection but has evolved into a comprehensive hardware + software ecosystem. Their product suite includes in-room activity sensing (AUGi), high-risk bathroom coverage (Sense), staff location tracking (Staff Beacon), resident help buttons, and an AI-driven software platform (Inspiren HQ) that gives operators real-time intelligence across their entire community. What makes this compelling is that they’re collapsing multiple point solutions — emergency pendants, basic call buttons, fragmented EHRs — into one cohesive platform that’s easier to deploy, scales across facilities, and delivers measurable ROI through improved safety, faster response times, and better staff utilization. They’ve proven retention and ACV expansion with operators, and they get devices ‘on walls’ faster than anyone else.</p><p><a href="https://www.augusthealth.com/">August Health</a> takes a similar platform approach but from a software-first angle. Founded by a former Landmark Health medical director and an ex-Apple engineering leader, August Health is an AI-enabled EHR platform that handles the full spectrum of senior living operations: digital move-ins, medication management (eMAR), care tracking, billing and payments, and operational insights. About 74% of senior living communities still run on paper, and most legacy systems were built for other industries and retrofitted for assisted living. August Health built purpose-designed software that’s intuitive for staff to use while delivering predictive intelligence on resident health and operations. They raised $29M in Series B in August 2025 and now serve thousands of communities across the U.S. and Canada. Early customers report a 23% reduction in incidents, a 20% increase in revenue, and millions of dollars in previously untracked care services identified. Among clinical staff, 87% say August Health improves care quality, and 4 in 5 report improved job satisfaction — critical in an industry facing persistent staffing shortages.</p><p><strong>Why this matters:</strong> Senior living is a massive, fragmented market where operators are under financial and operational pressure. A unified platform that makes care safer and operations more efficient is a category-defining opportunity — especially if you can get deployment right and build network effects at the facility and operator level. The difference between Inspiren’s hardware-first approach and August Health’s software-first approach shows there’s room for multiple winners depending on go-to-market motion and product philosophy.</p><h3>(2) Behavioral Health, Loneliness &amp; Cognitive Decline</h3><p>Behavioral health in seniors is deeply unmet:</p><ul><li>Seniors don’t self-refer</li><li>Symptoms present differently</li><li>Stigma is higher</li><li>Comorbidities complicate care</li></ul><p>Add to this:</p><ul><li>Loneliness (a clinical risk factor)</li><li>Dementia care needs</li><li>Cognitive maintenance</li></ul><p>…and you have one of the most underbuilt areas of healthcare.</p><p>These companies operate at the intersection of behavioral, social, and cognitive health, selling primarily to MA plans, ACOs, IDNs, and other risk-bearing entities with an ROI tied to early identification, engagement, and measurable reductions in avoidable utilization.</p><p><strong>Examples:</strong></p><ul><li><strong>Behavioral health:</strong><a href="https://www.vitalichealth.co/"><strong> Vitalic Health</strong></a><strong> (Seed), </strong><a href="https://authorhealth.com/"><strong>Author Health</strong></a><strong> (Series A)</strong></li><li><strong>Loneliness &amp; social connection:</strong><a href="https://www.intuitionrobotics.com/"><strong> Intuition Robotics</strong></a><strong> (Series C)</strong></li><li><strong>Dementia care &amp; cognitive maintenance:</strong><a href="https://www.myisaachealth.com/"><strong> Isaac Health</strong></a><strong> (Series A),</strong><a href="https://ripplcare.com/"><strong> Rippl</strong></a><strong> (Series A), </strong><a href="https://www.synapticure.com/"><strong>Synapticure</strong></a><strong> (Series A), </strong><a href="https://www.newdays.ai/"><strong>NewDays</strong></a><strong> (Seed)</strong></li></ul><p><a href="https://www.vitalichealth.co/">Vitalic Health</a> focuses on identifying and treating depression and anxiety in older adults — conditions that are common yet chronically underdiagnosed. Their model is designed specifically for seniors: consumer-informed outreach co-branded with a patient’s PCP, destigmatized language, and a multidisciplinary team trained in geriatric behavioral health. A key differentiator is their evidence-based approach. Vitalic partners with academic institutions, including the University of Rochester, with early data showing ~50% improvement on PHQ-9 and ~36% total cost-of-care reduction. These outcomes provide rare, clinically validated proof points in this category. They also strategically position their offering not simply as “behavioral health,” but as a cost-reduction and care-gap closure solution — framing that resonates strongly with risk-bearing entities managing total cost of care.</p><p><a href="https://www.intuitionrobotics.com/">Intuition Robotics</a> tackles behavioral and cognitive decline through the lens of loneliness — now recognized as a clinical risk factor on par with chronic disease. Its AI companion, ElliQ, delivers conversation, proactive check-ins, behavioral nudges, and cognitive engagement prompts to help seniors maintain routines, feel connected, and stay mentally stimulated. Early deployments show strong engagement and meaningful improvements in perceived wellness and connection. The platform bridges social health, mental health, and daily-function support — a combination that traditional healthcare models rarely address and one that fills a growing gap for risk-bearing entities managing aging-in-place populations.</p><p>“For too long, people experiencing cognitive changes have been told there’s nothing they can do beyond maintaining a healthy lifestyle and preparing for decline.” Grounded in this insight from CEO Babak Parviz, <a href="https://www.newdays.ai/">NewDays</a> delivers evidence-based cognitive interventions through an AI companion that uses natural, personalized conversations and guided exercises to support older adults every day. Its hybrid model — AI presence plus access to clinical experts — offers continuous, dignified care that strengthens cognition, connection, and independence between medical visits.</p><p><strong>Why this matters:</strong> Behavioral health, loneliness, and cognitive decline are deeply intertwined for older adults. Traditional providers assume patients will self-refer, which simply doesn’t reflect how seniors engage with care. As CMS’s V28 recalibration forces payers to prioritize real clinical interventions over documentation-driven revenue, solutions that surface high-value diagnoses and address root drivers of utilization (isolation, depression, anxiety, cognitive decline) are becoming essential.</p><h3>Coming Up Next</h3><p>This is Part 1 of a three-part series breaking down where the senior care system is evolving and where new, durable venture opportunities lie.</p><p>In Part 2, I’ll dive into the remaining categories (#3–#6):</p><ul><li>Integrated home-based care / PACE</li><li>MA enablement</li><li>Caregiver support &amp; navigation</li><li>Home health clinical + RCM infrastructure</li></ul><p>And I’ll break down what these categories reveal about where senior care is actually heading — and the kinds of companies that are best positioned to win.</p><p><strong>→ To be continued in Part 2…</strong></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=7ef3dd155870" width="1" height="1" alt="">]]></content:encoded>
        </item>
    </channel>
</rss>